<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Food Nutr Res</journal-id><journal-id journal-id-type="iso-abbrev">Food Nutr Res</journal-id><journal-id journal-id-type="publisher-id">FNR</journal-id><journal-title-group><journal-title>Food &#x00026; Nutrition Research</journal-title></journal-title-group><issn pub-type="epub">1654-661X</issn><publisher><publisher-name>Co-Action Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27989269</article-id><article-id pub-id-type="pmc">5165058</article-id><article-id pub-id-type="publisher-id">29272</article-id><article-id pub-id-type="doi">10.3402/fnr.v60.29272</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Dietary tryptophan depletion in humans using a simplified two amino acid formula &#x02013; a pilot study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Linden</surname><given-names>Maike</given-names></name><xref ref-type="aff" rid="AF0001">1</xref><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Helmbold</surname><given-names>Katrin</given-names></name><xref ref-type="aff" rid="AF0001">1</xref><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Kempf</surname><given-names>Janina</given-names></name><xref ref-type="aff" rid="AF0001">1</xref><xref ref-type="aff" rid="AF0002">2</xref><xref ref-type="aff" rid="AF0003">3</xref></contrib><contrib contrib-type="author"><name><surname>Sippas</surname><given-names>Shabnam</given-names></name><xref ref-type="aff" rid="AF0001">1</xref><xref ref-type="aff" rid="AF0002">2</xref><xref ref-type="aff" rid="AF0003">3</xref></contrib><contrib contrib-type="author"><name><surname>Filss</surname><given-names>Christian</given-names></name><xref ref-type="aff" rid="AF0004">4</xref></contrib><contrib contrib-type="author"><name><surname>Langen</surname><given-names>Karl-Josef</given-names></name><xref ref-type="aff" rid="AF0004">4</xref><xref ref-type="aff" rid="AF0005">5</xref><xref ref-type="aff" rid="AF0006">6</xref></contrib><contrib contrib-type="author"><name><surname>Eisert</surname><given-names>Albrecht</given-names></name><xref ref-type="aff" rid="AF0007">7</xref></contrib><contrib contrib-type="author"><name><surname>Zepf</surname><given-names>Florian Daniel</given-names></name><xref ref-type="aff" rid="AF0001">1</xref><xref ref-type="aff" rid="AF0002">2</xref><xref ref-type="aff" rid="AF0008">8</xref><xref ref-type="aff" rid="AF0009">9</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib></contrib-group><aff id="AF0001"><label>1</label>Clinic for Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, RWTH Aachen University, Aachen, Germany</aff><aff id="AF0002"><label>2</label>JARA Translational Brain Medicine, J&#x000fc;lich Aachen Research Alliance, J&#x000fc;lich, Germany</aff><aff id="AF0003"><label>3</label>Faculty of Arts and Social Sciences, Maastricht University, Maastricht, The Netherlands</aff><aff id="AF0004"><label>4</label>Section JARA-Brain, J&#x000fc;lich-Aachen Research Alliance (JARA), J&#x000fc;lich, Germany</aff><aff id="AF0005"><label>5</label>Institute of Neuroscience and Medicine (INM-3, -4, -5), Research Centre J&#x000fc;lich, J&#x000fc;lich, Germany</aff><aff id="AF0006"><label>6</label>Department of Nuclear Medicine, RWTH Aachen University Hospital, Aachen, Germany</aff><aff id="AF0007"><label>7</label>Department of Pharmacy, RWTH Aachen University, Aachen, Germany</aff><aff id="AF0008"><label>8</label>Centre and Discipline of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, School of Psychiatry and Clinical Neurosciences &#x00026; School of Paediatrics and Child Health, Faculty of Medicine, Dentistry and Health Sciences, The University of Western Australia, Perth, Australia</aff><aff id="AF0009"><label>9</label>Specialised Child and Adolescent Mental Health Services (CAMHS), Department of Health in Western Australia, Perth, Australia</aff><author-notes><corresp id="cor1"><label>*</label><bold>Florian Daniel Zepf</bold>, Centre and Discipline of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University of Western Australia, 35 Stirling Highway (M561), Crawley WA 6009, Perth, Australia. Email: <email xlink:href="florian.zepf@uwa.edu.au">florian.zepf@uwa.edu.au</email></corresp></author-notes><pub-date pub-type="epub"><day>16</day><month>12</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>60</volume><elocation-id content-type="doi">10.3402/fnr.v60.29272</elocation-id><history><date date-type="received"><day>26</day><month>7</month><year>2015</year></date><date date-type="rev-recd"><day>26</day><month>9</month><year>2016</year></date><date date-type="accepted"><day>03</day><month>11</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; 2016 Maike Linden et al.</copyright-statement><copyright-year>2016</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for any purpose, even commercially, provided the original work is properly cited and states its license.</license-p></license></permissions><abstract><sec id="st1"><title>Background</title><p>Acute tryptophan depletion (ATD) is a well-established dietary method in translational brain research used to briefly lower central nervous serotonin (5-hydroxytryptamine (5-HT)) synthesis. A simplified two amino acid ATD formula (ATD<sub>PHE/LEU</sub>) was developed while reducing the overall amount of amino acids (AAs), with the objective of administration especially in children and adolescents in future studies.</p></sec><sec id="st2"><title>Objective</title><p>This study investigated tryptophan (TRP) influx rates across the blood-brain barrier (BBB) after dietary ATD<sub>PHE/LEU</sub> administration relative to the ATD Moja-De protocol that has been established for use in children and adolescents.</p></sec><sec id="st3"><title>Design</title><p>Seventy-two healthy adults (50% females) were randomized into four groups and administered ATD Moja-De, its TRP-balanced control condition (BAL), ATD<sub>PHE/LEU</sub>, or its respective control mixture (BAL<sub>PHE/LEU</sub>) in a counterbalanced, double-blind, between-subjects design. Blood samples were collected at baseline and at hourly intervals for 6 h after AA intake. Questionnaires about mood, taste, and challenge tolerance were completed at fixed time points.</p></sec><sec id="st4"><title>Results</title><p>Both challenge mixtures significantly reduced central nervous TRP influx as calculated by Michaelis&#x02013;Menten kinetics relative to baseline and the respective control conditions with only mild and comparable side effects. A greater decline in TRP influx over the BBB after ATD<sub>PHE/LEU</sub> administration when compared with ATD Moja-De was detected without group effects for taste, challenge tolerance, and mood. There was unintended initial short increase in plasma TRP concentrations observed after ATD<sub>PHE/LEU</sub> intake, and a possible redistribution between free and protein-bound TRP triggered by protein synthesis stimulated by the ingested AAs may account for this finding. Moreover, a decline in TRP influx after BAL<sub>PHE/LEU</sub> administration over a 6-h period was observed, and the large amount of PHE in the BAL<sub>PHE/LEU</sub> mixture may be a possible explanation for this particular phenomenon, which could have led to an unexpected increase in displacement of TRP at the BBB in this control condition.</p></sec><sec id="st5"><title>Conclusions</title><p>This pilot study provides preliminary evidence for the possibility of lowering TRP influx as calculated by Michaelis&#x02013;Menten kinetics into the brain by using a simplified ATD protocol in humans. The simplified composition of only two AAs, the lower overall AA amount, and the appropriate tolerance are characteristics of the newly developed ATD<sub>PHE/LEU</sub> protocol. Future studies focusing on the effects of the ATD<sub>PHE/LEU</sub> protocol and its respective control condition on CSF 5-HIAA concentrations, as well as neurochemical studies in rodents, are needed to further validate this newly developed AA mixture before definite conclusions about its usability in ATD-related research in humans, its specificity, and additional effects can be made.</p></sec></abstract><kwd-group><kwd>serotonin</kwd><kwd>amino acids</kwd><kwd>dietary tryptophan depletion</kwd><kwd>influx rate</kwd><kwd>Michaelis&#x02013;Menten kinetics</kwd><kwd>humans</kwd></kwd-group></article-meta></front><body><p>Acute tryptophan depletion (ATD) is an established dietary challenge procedure used to investigate the central nervous effects of the neurotransmitter serotonin (5-hydroxytryptamine (5-HT)) in humans and rodents by a short term and reversible reduction in the brain 5-HT synthesis rate. This method has been commonly used in translational brain research for more than 25 years and is of both clinical and scientific relevance, particularly because 5-HT modulates an extensive range of physiological and behavioral functions (<xref rid="CIT0001" ref-type="bibr">1</xref>). Moreover, it is known to be involved in the pathogenesis and pathophysiology of a variety of different behaviors and neuropsychiatric disorders, including affective, eating, and attention deficit hyperactivity disorders (<xref rid="CIT0002" ref-type="bibr">2</xref>&#x02013;<xref rid="CIT0013" ref-type="bibr">13</xref>).</p><p>ATD is accomplished through the administration of a mixture of large neutral amino acids (LNAAs) lacking tryptophan (TRP). Because 5-HT is not able to pass the blood-brain barrier (BBB), it is synthesized from its physiological precursor, the amino acid (AA) TRP, in the brain. A small proportion of TRP reaches the central nervous system through passive diffusion. The majority of free TRP uses the active transport system L-1, a carrier in the capillary cell plasma membrane specialized for the transportation of all LNAAs, to cross the BBB (<xref rid="CIT0014" ref-type="bibr">14</xref>). An affinity to the aforementioned AA, increased by 100&#x02013;1,000 times, characterizes the BBB-specific type of the L-1 system (<xref rid="CIT0015" ref-type="bibr">15</xref>). Moreover, L-systems differing in these and other properties can be found in all cell types in the human body (e.g. gastrointestinal tractus and hepatic and renal tissues). The uptake of TRP into the brain using L-1, which is saturated under physiological conditions, marks a facilitated diffusion that follows Michaelis&#x02013;Menten kinetics with competitive substrate inhibition of the LNAAs at the common transporter (<xref rid="CIT0015" ref-type="bibr">15</xref>&#x02013;<xref rid="CIT0017" ref-type="bibr">17</xref>). When orally administering a beverage of LNAAs lacking TRP, it was shown that TRP plasma concentrations decline because of increased protein synthesis in the liver, which is induced by the administered AA load. Based on preliminary findings in rats (<xref rid="CIT0018" ref-type="bibr">18</xref>), this is thought to be an underlying principle of the ATD challenge procedure introduced by Young et al. because of reduced substrate availability for brain 5-HT synthesis with regard to reduced plasma TRP levels. Moreover, ATD makes use of the outlined competitive substrate inhibition, resulting in a diminished uptake of endogenous TRP into the central nervous system at L-1 (<xref rid="CIT0019" ref-type="bibr">19</xref>&#x02013;<xref rid="CIT0023" ref-type="bibr">23</xref>). Specifically, the administered AAs compete with endogenous TRP at L-1 for uptake into the central nervous system. The synthesis of 5-HT in the brain comprises two steps: first, the hydroxylation of TRP by the tryptophan hydroxylase 2 (TPH2) into 5-hydroxytryptophan, followed by a 5-hydroxytryptophan decarboxylase catalysis in the second step, which leads to 5-HT (<xref rid="CIT0024" ref-type="bibr">24</xref>, <xref rid="CIT0025" ref-type="bibr">25</xref>). TPH2 is involved in the rate-limiting step of the central nervous 5-HT synthesis pathway, with TPH2 showing a saturation of approximately 50% under physiological conditions (<xref rid="CIT0026" ref-type="bibr">26</xref>). As a consequence, reduced substrate availability of TRP due to competing mechanisms at the L-1 when other AAs are administered leads to a lowered central nervous 5-HT synthesis rate. As outlined above, AA administration is thought to induce restricted 5-HT synthesis by stimulating protein synthesis in the liver with the consumption of additional TRP from plasma stores (<xref rid="CIT0026" ref-type="bibr">26</xref>, <xref rid="CIT0027" ref-type="bibr">27</xref>).</p><p>The history of ATD development is characterized by a variety of modifications of the respective AA mixtures. In 1977, Concu et al. (<xref rid="CIT0028" ref-type="bibr">28</xref>) applied the ATD technique to humans using 18.2 g of a TRP-free mixture (containing L-glycine, L-lysine (LYS), L-methionine (MET), L-phenylalanine (PHE), L-leucine (LEU), L-isoleucine (ILE), L-threonine (THR), and L-valine (VAL)). They detected a decline in serum TRP by 42% in healthy men (<xref rid="CIT0029" ref-type="bibr">29</xref>). Moja et al. (<xref rid="CIT0030" ref-type="bibr">30</xref>) also tested a similar formulation, lacking glycine, in healthy male subjects. In their study, plasma TRP decreased to ~35% of the initial level following the administration of an AA dose of 36.6 g. Most of the published ATD studies refer to a protocol introduced by Young et al. (<xref rid="CIT0031" ref-type="bibr">31</xref>). Young and colleagues used a 100 g mixture of 15 amino acids (nine LNAA and six non-essential AAs) and found a 76% decrease in plasma TRP. This formulation can cause a large range of side effects (such as nausea, vomiting, headache, and dizziness), which were also reported in other ATD studies (<xref rid="CIT0002" ref-type="bibr">2</xref>, <xref rid="CIT0020" ref-type="bibr">20</xref>, <xref rid="CIT0032" ref-type="bibr">32</xref>&#x02013;<xref rid="CIT0035" ref-type="bibr">35</xref>). Dougherty et al. (<xref rid="CIT0021" ref-type="bibr">21</xref>) found that reducing the amino acid dose to only 50 g helped diminish observed side effects while implying a slightly less robust depletion when compared with the 100 g formulation.</p><p>ATD Moja-De, a modification of the formulation by Moja et al. (<xref rid="CIT0030" ref-type="bibr">30</xref>), was developed in 2002 (<xref rid="CIT0036" ref-type="bibr">36</xref>, <xref rid="CIT0037" ref-type="bibr">37</xref>) with the aim of establishing a body weight-adapted dosing regimen that can be used in minors. This concept does not only help to reduce side effects to a tolerable level but also allows the application of ATD Moja-De to children and adolescents as well as adults, opening further developmental research perspectives for future studies. Moreover, ATD Moja-De is the only available ATD formulation to date that has been shown to decrease brain 5-HT in mice (<xref rid="CIT0038" ref-type="bibr">38</xref>).</p><p>Based on the above mentioned developments, we decided to establish a new formulation, called ATD<sub>PHE/LEU</sub>, for optimizing TRP depletion procedures in healthy adult humans. Once data in adult humans are obtained as proposed in this study, this formulation could potentially be used for future studies in children and adolescents. Our motivation was to introduce a new protocol for a possible later use in children and adolescents allowing a reduction of the overall AA amount and a less complex composition, leading to a solid depletion magnitude while reducing or maintaining the very low side effects established in ATD Moja-De. Hence, a new protocol was developed based on mathematical considerations and existing data that showed differing affinities of competing AAs to L-1 (<xref rid="CIT0016" ref-type="bibr">16</xref>), thus impacting TRP influx over the BBB to the greatest extent. ATD<sub>PHE/LEU</sub> was intended to consist of two AAs, PHE and LEU, as these show the highest affinities to the L-1 transporting enzyme of all competing LNAAs (<xref rid="CIT0016" ref-type="bibr">16</xref>, <xref rid="CIT0036" ref-type="bibr">36</xref>). Therefore, based on a recent study confirming the effectiveness of a similar simplified protocol in a mouse model (<xref rid="CIT0012" ref-type="bibr">12</xref>), we expected adequate stimulation of protein synthesis in the liver (thus leading to a decline in plasma TRP) and a more effective displacement of TRP by PHE and LEU at the common BBB transporter.</p><p>The primary aim of this study was to make a comparison of the new dietary depletion protocol's efficacy against that of the established ATD Moja-De, contrasting challenge conditions (ATD, ATD<sub>PHE/LEU</sub>) and their counterbalanced control conditions (BAL, BAL<sub>PHE/LEU</sub>) in healthy adults. We collected several blood samples over a defined time interval and calculated TRP influx rates across the BBB using Michaelis&#x02013;Menten kinetics with a correction for multiple substrate inhibition.</p><sec sec-type="methods" id="S0002"><title>Methods</title><sec id="S0002-S20001"><title>Study design</title><p>The study employed a controlled, double-blind, between-subjects design. One of the four different AA mixtures, ATD Moja-De, BAL (a TRP-balanced AA load serving as a control condition for ATD Moja-De), ATD<sub>PHE/LEU</sub> (the new ATD AA mixture), or BAL<sub>PHE/LEU</sub> (the newly developed control condition for ATD<sub>PHE/LEU</sub>), was administered to a sample group of healthy adult subjects. Blood samples were collected at hourly intervals for 6 h. Participants also completed questionnaires on mood, challenge tolerance, and taste evaluations.</p></sec><sec id="S0002-S20002"><title>Ethics statement</title><p>The ethics committee of the Medical Faculty of the RWTH Aachen University, Germany, evaluated and approved the study protocol. The study was carried out in accordance with the Declaration of Helsinki. All participants provided oral and written informed consent. After completion of all measurements, participants were financially compensated.</p></sec><sec id="S0002-S20003"><title>Sample</title><p>Participants were recruited through local advertisements. A total of 72 subjects (50% females) aged between 18 and 33 years (mean age 23.60&#x000b1;3.08 years) participated in the study. All subjects were right-handed native German speakers who did not suffer from any physical (excluded by interview) or psychiatric disorder (evaluated by a standardized screening interview for psychiatric disorders, the SKIDPIT-light (<xref rid="CIT0039" ref-type="bibr">39</xref>)). The exclusion criteria included the following: an IQ lower than 85; smoking; the use of regular medications excluding oral contraceptives; drug abuse; pregnancy; psychoorganic syndromes; schizophrenia; affective disorders; and neurological and somatic diseases such as migraines, asthma, diabetes, metabolic or hormonal disorders, allergies or obesity. The mean BMI of the participants was 22.4&#x000b1;2.5 kg/m<sup>2</sup>. Using the CFT-20R (<xref rid="CIT0040" ref-type="bibr">40</xref>), the participants&#x02019; IQ (mean IQ=112&#x000b1;13.6) was assessed. Approximately 20 individuals were excluded by these criteria during the recruitment process. Primary pre-screening for inclusion/exclusion criteria was conducted by telephonic interview. Written informed consent was obtained after in-person screening and clarification by a doctor. Subjects verified by self-report that they had followed the instructions regarding beverage and food intake. Negative urine drug screens and pregnancy tests were required before the administration of the AA beverages. The complete descriptive data of the sample are given in <xref ref-type="table" rid="T0001">Table 1</xref>.</p><table-wrap id="T0001" position="float"><label>Table 1</label><caption><p>Descriptive data of the study sample</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="2" rowspan="1"/><th align="center" rowspan="1" colspan="1">ATD</th><th align="center" rowspan="1" colspan="1">BAL</th><th align="center" rowspan="1" colspan="1">ATD<sub>PHE/LEU</sub></th><th align="center" rowspan="1" colspan="1">BAL<sub>PHE/LEU</sub></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="left" rowspan="1" colspan="1">M&#x000b1;SD</td><td align="center" rowspan="1" colspan="1">23.11&#x000b1;2.89</td><td align="center" rowspan="1" colspan="1">23.94&#x000b1;3.15</td><td align="center" rowspan="1" colspan="1">23.67&#x000b1;2.66</td><td align="center" rowspan="1" colspan="1">23.72&#x000b1;3.69</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Min.</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">19</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Max.</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">32</td><td align="center" rowspan="1" colspan="1">29</td><td align="center" rowspan="1" colspan="1">33</td></tr><tr><td align="left" rowspan="1" colspan="1">IQ</td><td align="left" rowspan="1" colspan="1">M&#x000b1;SD</td><td align="center" rowspan="1" colspan="1">107.67&#x000b1;16.36</td><td align="center" rowspan="1" colspan="1">113.22&#x000b1;12.10</td><td align="center" rowspan="1" colspan="1">114.61&#x000b1;14.97</td><td align="center" rowspan="1" colspan="1">112.89&#x000b1;10.27</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Min.</td><td align="center" rowspan="1" colspan="1">80</td><td align="center" rowspan="1" colspan="1">97</td><td align="center" rowspan="1" colspan="1">76</td><td align="center" rowspan="1" colspan="1">97</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Max.</td><td align="center" rowspan="1" colspan="1">138</td><td align="center" rowspan="1" colspan="1">142</td><td align="center" rowspan="1" colspan="1">142</td><td align="center" rowspan="1" colspan="1">134</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI</td><td align="left" rowspan="1" colspan="1">M&#x000b1;SD</td><td align="center" rowspan="1" colspan="1">22.90&#x000b1;2.53</td><td align="center" rowspan="1" colspan="1">22.18&#x000b1;2.81</td><td align="center" rowspan="1" colspan="1">22.21&#x000b1;2.52</td><td align="center" rowspan="1" colspan="1">22.25&#x000b1;2.41</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Min.</td><td align="center" rowspan="1" colspan="1">18.8</td><td align="center" rowspan="1" colspan="1">17.9</td><td align="center" rowspan="1" colspan="1">19.4</td><td align="center" rowspan="1" colspan="1">18.8</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Max.</td><td align="center" rowspan="1" colspan="1">27.3</td><td align="center" rowspan="1" colspan="1">29.0</td><td align="center" rowspan="1" colspan="1">29.4</td><td align="center" rowspan="1" colspan="1">26.9</td></tr></tbody></table><table-wrap-foot><fn><p>Descriptive data of the study sample are divided into four conditions/groups: acute tryptophan depletion mixture Moja-De (ATD), the TRP-balanced control condition for ATD Moja-De (BAL), the new ATD amino acid mixture (ATD<sub>PHE/LEU</sub>), or the newly developed control condition for ATD<sub>PHE/LEU</sub> (BAL<sub>PHE/LEU</sub>). Mean&#x000b1;standard deviation (M&#x000b1;SD), maximum (Max.), and minimum (Min.) values are listed for age, IQ, and body mass index (BMI).</p></fn></table-wrap-foot></table-wrap></sec><sec id="S0002-S20004"><title>Depletion procedure</title><p>Measurements began at the same time each morning in order to avoid the influence of circadian rhythms on metabolism and central nervous 5-HT synthesis. The AA beverages were administered between 9:00 and 10:00 a.m. The study duration was approximately 6 h. The participants were instructed to abstain from food high in protein beginning at 8:00 p.m. the night before each study day, and they were not allowed to drink any beverages other than water. They received a standardized low-protein breakfast (carbohydrate 68.3 g, fat 1.13 g, protein 5.1 g, and dietary fiber 2.3 g) containing two wheat rolls as well as one small pack of jam (25 g) and honey (25 g) immediately following the administration of the AA beverages with a 20-min time frame for breakfast. The particular AA mixtures were composed by a pharmacist and delivered within an aqueous suspension. In order to reduce the risk of undesired lump formation, the crystalline amino acids were solubilized as much as possible with a low sugar substitute in an amount of 200 ml of water using a milk frother. Beverage intake period was reduced to a minimum of approximately 3 min. The sample was divided into four randomized and counterbalanced groups of 18 people with equal gender distributions (9 women and 9 men). The administration of the different AA beverages was counterbalanced for sex. Participants of each group either received ATD, BAL, ATD<sub>PHE/LEU</sub>, or BAL<sub>PHE/LEU</sub>.</p><p>The neurodietary challenge procedure ATD Moja-De was previously used successfully with children and adolescents and had few side effects due to the administration regimen that adapted dosage to body weight (<xref rid="CIT0026" ref-type="bibr">26</xref>, <xref rid="CIT0036" ref-type="bibr">36</xref>&#x02013;<xref rid="CIT0038" ref-type="bibr">38</xref>, <xref rid="CIT0041" ref-type="bibr">41</xref>&#x02013;<xref rid="CIT0044" ref-type="bibr">44</xref>). The dosage per 10 kg of body weight contained L-PHE (1.32 g), L-LEU (1.32 g), L-ILE (0.84 g), L-MET (0.5 g), L-VAL (0.96 g), L-THR (0.6 g), and L-LYS (0.96 g). TRP (0.7 g per 10 kg of body weight) was added to the corresponding control condition (BAL). The newly developed AA mixture (ATD<sub>PHE/LEU</sub>), also dosed per 10 kg of body weight, consisted only of L-PHE (3.2 g) and L-LEU (3.0 g); BAL<sub>PHE/LEU</sub>, the new mixture's control condition, contained an additional dose of 0.7 g of TRP per 10 kg of body weight.</p></sec><sec id="S0002-S20005"><title>Blood samples</title><p>Blood samples (BS) were collected using a permanent venous catheter at baseline (T<sub>0</sub>) and each hour (T<sub>1</sub>, T<sub>2</sub>, T<sub>3</sub>, T<sub>4</sub>, T<sub>5</sub>, and T<sub>6</sub>) after the intake of ATD, BAL, ATD<sub>PHE/LEU</sub>, or BAL<sub>PHE/LEU</sub> (BS<sub>0</sub>, BS<sub>1</sub>, BS<sub>2</sub>, BS<sub>3</sub>, BS<sub>4</sub>, BS<sub>5</sub>, and BS<sub>6</sub>), resulting in seven blood samples per subject. A 9-ml Ethylenediaminetetraacetic acid (EDTA-Tube) (EDTA S-Monovette<sup>&#x000ae;</sup>, Sarstedt, Germany) and one 7.5-ml Serum-Tube (Serum S-Monovette<sup>&#x000ae;</sup>, Sarstedt, Germany) were used for sample collection each hour. To avoid falsification of the blood values, the first 4.5 ml of every sample was rejected. The collected blood samples were kept at room temperature for 20 min and centrifuged at 2,500 g for 10 min. The resulting clear supernatant was removed with a pipette and kept in 2-ml Eppendorf Tubes<sup>&#x000ae;</sup> at &#x02212;80&#x000b0;C until transportation to the laboratory.</p><p>For the TRP influx calculations, plasma levels of PHE, Tyrosine (TYR), and TRP were measured using enzyme-linked immunosorbent assay (ELISA) kits (Immundiagnostik AG, Bensheim, Germany) in accordance with the manufacturer's instructions. The detection of the branched-chained AAs (BCAA: LEU, ILE and VAL) concentration using a BCAA test kit (Immundiagnostik AG, Bensheim, Germany) for photometric analyses of enzyme levels in plasma and serum was carried out according to the manufacturer's instructions. Information regarding sensitivity and specificity of the employed test kits is provided in <xref ref-type="supplementary-material" rid="S1">Supplementary Table 1</xref>.</p></sec><sec id="S0002-S20006"><title>Influx calculation into the brain for TRP, TYR, and PHE</title><p>We calculated the influx of TRP across the BBB using Michaelis&#x02013;Menten kinetics with a correction for multiple substrate competition, which is an established procedure in ATD-related research (<xref rid="CIT0016" ref-type="bibr">16</xref>, <xref rid="CIT0045" ref-type="bibr">45</xref>). As the competitive substrate inhibition of TRP and the LNAAs at the common transporting enzyme L-1 determines the uptake of TRP into the brain, this equation provides a valid mathematical model for calculating the unidirectional TRP influx rates into the central nervous system (<xref rid="CIT0026" ref-type="bibr">26</xref>, <xref rid="CIT0036" ref-type="bibr">36</xref>, <xref rid="CIT0046" ref-type="bibr">46</xref>). The equation (see <xref ref-type="supplementary-material" rid="S1">Supplementary file</xref>) includes both components influencing TRP uptake: the facilitated diffusion of AAs at L-1 and passive diffusion (<xref rid="CIT0036" ref-type="bibr">36</xref>). Influx rates of the competing LNAAs PHE, TYR, as well as BCAA influx were calculated using the same equation. In addition to the abovementioned influx calculations, we also provided the following ratios to ensure comparability with previous ATD studies: [TRP]/[CAA], [TYR]/[CAA], [PHE]/[CAA], and [PHE+TYR]/[BCAA+TRP] (CAA=competing amino acids). These ratios predict the entry rates of the involved amino acids into the brain and present another possible approach for evaluating ATD protocols.</p></sec><sec id="S0002-S20007"><title>Questionnaires</title><sec><title>Mood</title><p>The German version of the Positive and Negative Affect Schedule (PANAS) (<xref rid="CIT0047" ref-type="bibr">47</xref>) containing 10 items for positive (PA) and 10 items for negative (NA) affect was used to measure the extent to which depletion influenced the subjects&#x02019; mood state. Participants rated the intensity of each item on a five-point Likert scale (from 1=not at all to 5=very much) at baseline and every hour before the collection of the blood samples.</p></sec><sec><title>Challenge tolerance</title><p>We developed an in-house questionnaire on the tolerance of the AA challenges to detect if the newly developed mixture caused an equal amount of side effects as the established ATD Moja-De procedure. The questionnaire contained 12 items rated from 0 (disagree) to 3 (strongly agree). For evaluation purposes, we summarized the matching items and calculated a somatic complaints score, an awakeness score, and a hunger score. The common side effects observed in previous ATD studies, namely, headache, nausea, vomiting, dizziness, and sweating (<xref rid="CIT0048" ref-type="bibr">48</xref>), were included in this questionnaire (the entire questionnaire is available in the <xref ref-type="supplementary-material" rid="S1">Supplementary file</xref>). Participants completed this questionnaire every hour and immediately before and after the intake of the AA beverages.</p></sec><sec><title>Taste</title><p>For taste evaluation, an in-house questionnaire consisting of six items was employed (see <xref ref-type="supplementary-material" rid="S1">Supplementary file</xref>). The consistency, the sulfuric taste, the difficulty of intake, and revulsion were assessed using a scale of 0 (disagree) to 3 (strongly agree) immediately after the intake of the AA beverages.</p></sec></sec><sec id="S0002-S20008"><title>Statistical analysis</title><p>As primary analysis, the influence of the four different AA mixtures on TRP influx across the BBB was investigated using repeated measures analyses of variance (rmANOVAs) with treatment as the between-subjects factor, time as the within-subjects factor, and gender as a covariate in SPSS Version 21.0 for MacOS. The degrees of freedom for the ANOVA <italic>F</italic>-statistics were adjusted according to the Greenhouse&#x02013;Geisser correction for non-sphericity (<italic>p&#x0003c;</italic>0.05). Similar analyses were performed on TYR and PHE influx across the BBB, on [TRP]/[CAA] ratio, on tolerance (the somatic complaints score, awakeness score, and hunger score), and on the PA- and NA-PANAS scores over time. In addition, separate ANOVAs, with the Greenhouse&#x02013;Geisser correction, on the TRP influx for each group using time as a within-subjects factor were performed. One-way ANOVA was used to determine any significant differences in [TRP]/[CAA] ratio, in TRP, TYR, and PHE influx rates between the groups at baseline (T<sub>0</sub>). The influences of the different side effects (e.g. headache, nausea, vomiting, dizziness, and sweating), part of the somatic complaints score, were assessed by rmANOVAs with time as the within-subjects factor and treatment as the between-subjects factor. One-way ANOVA with gender as a covariate was employed to analyze taste differences between the four mixtures. Gaussian distribution for all dependent variables was established with the Kolmogorov&#x02013;Smirnov test for each of the four groups and for the groups formed by dividing the participants by gender. The level of statistical significance was set and kept at <italic>p</italic>&#x0003c;0.05. Because of the explorative nature of this study, alpha-adjustment was not employed. <italic>Post hoc</italic> power analyses were performed using G*Power Version 3.1.9.2. for MacOS.</p></sec></sec><sec sec-type="results" id="S0003"><title>Results</title><p>All plasma AA concentrations of TRP, PHE, TYR, and BCAA are presented in <xref ref-type="table" rid="T0002">Table 2</xref>. <xref ref-type="table" rid="T0003">Table 3</xref> includes all calculated influx values for TRP, TYR, PHE, (TYR+PHE), and BCAA across the BBB.</p><table-wrap id="T0002" position="float"><label>Table 2</label><caption><p>Blood concentrations of tryptophan, phenylalanine, tyrosine, and BCAA</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Parameter</th><th align="center" rowspan="1" colspan="1">Mixture</th><th align="center" rowspan="1" colspan="1">Baseline (T<sub>0</sub>)</th><th align="center" rowspan="1" colspan="1">T<sub>1</sub></th><th align="center" rowspan="1" colspan="1">T<sub>2</sub></th><th align="center" rowspan="1" colspan="1">T<sub>3</sub></th><th align="center" rowspan="1" colspan="1">T<sub>4</sub></th><th align="center" rowspan="1" colspan="1">T<sub>5</sub></th><th align="center" rowspan="1" colspan="1">T<sub>6</sub></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">[TRP] in &#x003bc;mol/l</td><td align="left" rowspan="1" colspan="1">ATD</td><td align="center" rowspan="1" colspan="1">70&#x000b1;3</td><td align="center" rowspan="1" colspan="1">117&#x000b1;22</td><td align="center" rowspan="1" colspan="1">111&#x000b1;23</td><td align="center" rowspan="1" colspan="1">95&#x000b1;22</td><td align="center" rowspan="1" colspan="1">83&#x000b1;22</td><td align="center" rowspan="1" colspan="1">75&#x000b1;23</td><td align="center" rowspan="1" colspan="1">69&#x000b1;17</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">BAL</td><td align="center" rowspan="1" colspan="1">68&#x000b1;3</td><td align="center" rowspan="1" colspan="1">418&#x000b1;22</td><td align="center" rowspan="1" colspan="1">437&#x000b1;23</td><td align="center" rowspan="1" colspan="1">393&#x000b1;22</td><td align="center" rowspan="1" colspan="1">372&#x000b1;22</td><td align="center" rowspan="1" colspan="1">261&#x000b1;23</td><td align="center" rowspan="1" colspan="1">178&#x000b1;17</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ATD<sub>PHE/LEU</sub></td><td align="center" rowspan="1" colspan="1">66&#x000b1;3</td><td align="center" rowspan="1" colspan="1">107&#x000b1;22</td><td align="center" rowspan="1" colspan="1">110&#x000b1;23</td><td align="center" rowspan="1" colspan="1">111&#x000b1;22</td><td align="center" rowspan="1" colspan="1">108&#x000b1;22</td><td align="center" rowspan="1" colspan="1">105&#x000b1;23</td><td align="center" rowspan="1" colspan="1">97&#x000b1;17</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">BAL<sub>PHE/LEU</sub></td><td align="center" rowspan="1" colspan="1">68&#x000b1;3</td><td align="center" rowspan="1" colspan="1">460&#x000b1;22</td><td align="center" rowspan="1" colspan="1">407&#x000b1;23</td><td align="center" rowspan="1" colspan="1">422&#x000b1;22</td><td align="center" rowspan="1" colspan="1">409&#x000b1;22</td><td align="center" rowspan="1" colspan="1">397&#x000b1;23</td><td align="center" rowspan="1" colspan="1">308&#x000b1;17</td></tr><tr><td align="left" rowspan="1" colspan="1">[PHE]</td><td align="left" rowspan="1" colspan="1">ATD</td><td align="center" rowspan="1" colspan="1">51&#x000b1;24</td><td align="center" rowspan="1" colspan="1">376&#x000b1;53</td><td align="center" rowspan="1" colspan="1">484&#x000b1;92</td><td align="center" rowspan="1" colspan="1">393&#x000b1;96</td><td align="center" rowspan="1" colspan="1">419&#x000b1;117</td><td align="center" rowspan="1" colspan="1">313&#x000b1;118</td><td align="center" rowspan="1" colspan="1">242&#x000b1;115</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">BAL</td><td align="center" rowspan="1" colspan="1">55&#x000b1;24</td><td align="center" rowspan="1" colspan="1">329&#x000b1;53</td><td align="center" rowspan="1" colspan="1">400&#x000b1;92</td><td align="center" rowspan="1" colspan="1">330&#x000b1;96</td><td align="center" rowspan="1" colspan="1">310&#x000b1;117</td><td align="center" rowspan="1" colspan="1">284&#x000b1;118</td><td align="center" rowspan="1" colspan="1">192&#x000b1;115</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ATD<sub>PHE/LEU</sub></td><td align="center" rowspan="1" colspan="1">112&#x000b1;24</td><td align="center" rowspan="1" colspan="1">972&#x000b1;53</td><td align="center" rowspan="1" colspan="1">1236&#x000b1;92</td><td align="center" rowspan="1" colspan="1">1457&#x000b1;96</td><td align="center" rowspan="1" colspan="1">1571&#x000b1;117</td><td align="center" rowspan="1" colspan="1">1427&#x000b1;118</td><td align="center" rowspan="1" colspan="1">1182&#x000b1;115</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">BAL<sub>PHE/LEU</sub></td><td align="center" rowspan="1" colspan="1">86&#x000b1;24</td><td align="center" rowspan="1" colspan="1">977&#x000b1;53</td><td align="center" rowspan="1" colspan="1">1474&#x000b1;92</td><td align="center" rowspan="1" colspan="1">1816&#x000b1;96</td><td align="center" rowspan="1" colspan="1">1926&#x000b1;117</td><td align="center" rowspan="1" colspan="1">1683&#x000b1;118</td><td align="center" rowspan="1" colspan="1">1416&#x000b1;115</td></tr><tr><td align="left" rowspan="1" colspan="1">[TYR]</td><td align="left" rowspan="1" colspan="1">ATD</td><td align="center" rowspan="1" colspan="1">59&#x000b1;4</td><td align="center" rowspan="1" colspan="1">108&#x000b1;8</td><td align="center" rowspan="1" colspan="1">120&#x000b1;13</td><td align="center" rowspan="1" colspan="1">109&#x000b1;14</td><td align="center" rowspan="1" colspan="1">100&#x000b1;14</td><td align="center" rowspan="1" colspan="1">94&#x000b1;15</td><td align="center" rowspan="1" colspan="1">88&#x000b1;12</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">BAL</td><td align="center" rowspan="1" colspan="1">55&#x000b1;4</td><td align="center" rowspan="1" colspan="1">97&#x000b1;8</td><td align="center" rowspan="1" colspan="1">97&#x000b1;13</td><td align="center" rowspan="1" colspan="1">85&#x000b1;14</td><td align="center" rowspan="1" colspan="1">79&#x000b1;14</td><td align="center" rowspan="1" colspan="1">71&#x000b1;15</td><td align="center" rowspan="1" colspan="1">60&#x000b1;12</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ATD<sub>PHE/LEU</sub></td><td align="center" rowspan="1" colspan="1">59&#x000b1;4</td><td align="center" rowspan="1" colspan="1">132&#x000b1;8</td><td align="center" rowspan="1" colspan="1">170&#x000b1;13</td><td align="center" rowspan="1" colspan="1">193&#x000b1;14</td><td align="center" rowspan="1" colspan="1">204&#x000b1;14</td><td align="center" rowspan="1" colspan="1">197&#x000b1;15</td><td align="center" rowspan="1" colspan="1">189&#x000b1;12</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">BAL<sub>PHE/LEU</sub>
</td><td align="center" rowspan="1" colspan="1">62&#x000b1;4</td><td align="center" rowspan="1" colspan="1">130&#x000b1;8</td><td align="center" rowspan="1" colspan="1">169&#x000b1;13</td><td align="center" rowspan="1" colspan="1">195&#x000b1;14</td><td align="center" rowspan="1" colspan="1">207&#x000b1;14</td><td align="center" rowspan="1" colspan="1">206&#x000b1;15</td><td align="center" rowspan="1" colspan="1">196&#x000b1;12</td></tr><tr><td align="left" rowspan="1" colspan="1">[BCAA]</td><td align="left" rowspan="1" colspan="1">ATD</td><td align="center" rowspan="1" colspan="1">416&#x000b1;20</td><td align="center" rowspan="1" colspan="1">1444&#x000b1;53</td><td align="center" rowspan="1" colspan="1">1458&#x000b1;56</td><td align="center" rowspan="1" colspan="1">1374&#x000b1;61</td><td align="center" rowspan="1" colspan="1">1251&#x000b1;57</td><td align="center" rowspan="1" colspan="1">1040&#x000b1;64</td><td align="center" rowspan="1" colspan="1">819&#x000b1;47</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">BAL</td><td align="center" rowspan="1" colspan="1">412&#x000b1;20</td><td align="center" rowspan="1" colspan="1">1278&#x000b1;53</td><td align="center" rowspan="1" colspan="1">1297&#x000b1;56</td><td align="center" rowspan="1" colspan="1">1249&#x000b1;61</td><td align="center" rowspan="1" colspan="1">1137&#x000b1;57</td><td align="center" rowspan="1" colspan="1">905&#x000b1;64</td><td align="center" rowspan="1" colspan="1">744&#x000b1;47</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ATD<sub>PHE/LEU</sub>
</td><td align="center" rowspan="1" colspan="1">405&#x000b1;20</td><td align="center" rowspan="1" colspan="1">1078&#x000b1;53</td><td align="center" rowspan="1" colspan="1">971&#x000b1;56</td><td align="center" rowspan="1" colspan="1">953&#x000b1;61</td><td align="center" rowspan="1" colspan="1">822&#x000b1;57</td><td align="center" rowspan="1" colspan="1">628&#x000b1;64</td><td align="center" rowspan="1" colspan="1">485&#x000b1;47</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">BAL<sub>PHE/LEU</sub>
</td><td align="center" rowspan="1" colspan="1">400&#x000b1;20</td><td align="center" rowspan="1" colspan="1">1024&#x000b1;53</td><td align="center" rowspan="1" colspan="1">945&#x000b1;56</td><td align="center" rowspan="1" colspan="1">973&#x000b1;61</td><td align="center" rowspan="1" colspan="1">827&#x000b1;57</td><td align="center" rowspan="1" colspan="1">604&#x000b1;64</td><td align="center" rowspan="1" colspan="1">446&#x000b1;47</td></tr></tbody></table><table-wrap-foot><fn><p>Plasma amino acid concentrations (in &#x000b5;mol/l) of tryptophan, phenylalanine, tyrosine, and branched-chain amino acids (BCAA; including valine, leucine, and isoleucine) after the administration of four different amino acid mixtures: ATD (acute tryptophan depletion; challenge condition), BAL (control condition for ATD), ATD<sub>PHE/LEU</sub> (newly developed challenge condition), and BAL<sub>PHE/LEU</sub> (control condition for ATD<sub>PHE/LEU</sub>). Mean values&#x000b1;standard error are given for the different groups (each including 18 subjects) at the seven time points of blood withdrawal (T0&#x02013;T6).</p></fn></table-wrap-foot></table-wrap><table-wrap id="T0003" position="float"><label>Table 3</label><caption><p>Calculated influx values of particular amino acids across the BBB</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Parameter</th><th align="center" rowspan="1" colspan="1">Mixture</th><th align="center" rowspan="1" colspan="1">Baseline (T<sub>0</sub>)</th><th align="center" rowspan="1" colspan="1">T<sub>1</sub>
</th><th align="center" rowspan="1" colspan="1">T<sub>2</sub>
</th><th align="center" rowspan="1" colspan="1">T<sub>3</sub>
</th><th align="center" rowspan="1" colspan="1">T<sub>4</sub>
</th><th align="center" rowspan="1" colspan="1">T<sub>5</sub>
</th><th align="center" rowspan="1" colspan="1">T<sub>6</sub>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">TRP-influx</td><td align="left" rowspan="1" colspan="1">ATD</td><td align="center" rowspan="1" colspan="1">13.573&#x000b1;0.479</td><td align="center" rowspan="1" colspan="1">6.912&#x000b1;0.603</td><td align="center" rowspan="1" colspan="1">6.004&#x000b1;0.609</td><td align="center" rowspan="1" colspan="1">5.715&#x000b1;0.645</td><td align="center" rowspan="1" colspan="1">4.897&#x000b1;0.637</td><td align="center" rowspan="1" colspan="1">5.485&#x000b1;0.752</td><td align="center" rowspan="1" colspan="1">6.452&#x000b1;0.552</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">BAL</td><td align="center" rowspan="1" colspan="1">13.313&#x000b1;0.479</td><td align="center" rowspan="1" colspan="1">17.190&#x000b1;0.603</td><td align="center" rowspan="1" colspan="1">16.533&#x000b1;0.609</td><td align="center" rowspan="1" colspan="1">16.821&#x000b1;0.645</td><td align="center" rowspan="1" colspan="1">16.864&#x000b1;0.637</td><td align="center" rowspan="1" colspan="1">14.122&#x000b1;0.752</td><td align="center" rowspan="1" colspan="1">14.236&#x000b1;0.552</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ATD<sub>PHE/LEU</sub>
</td><td align="center" rowspan="1" colspan="1">12.135&#x000b1;0.479</td><td align="center" rowspan="1" colspan="1">3.969&#x000b1;0.603</td><td align="center" rowspan="1" colspan="1">3.434&#x000b1;0.609</td><td align="center" rowspan="1" colspan="1">3.125&#x000b1;0.645</td><td align="center" rowspan="1" colspan="1">2.934&#x000b1;0.637</td><td align="center" rowspan="1" colspan="1">3.155&#x000b1;0.752</td><td align="center" rowspan="1" colspan="1">3.557&#x000b1;0.552</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">BAL<sub>PHE/LEU</sub>
</td><td align="center" rowspan="1" colspan="1">12.483&#x000b1;0.479</td><td align="center" rowspan="1" colspan="1">12.449&#x000b1;0.603</td><td align="center" rowspan="1" colspan="1">9.483&#x000b1;0.609</td><td align="center" rowspan="1" colspan="1">8.828&#x000b1;0.645</td><td align="center" rowspan="1" colspan="1">8.435&#x000b1;0.637</td><td align="center" rowspan="1" colspan="1">8.939&#x000b1;0.752</td><td align="center" rowspan="1" colspan="1">8.191&#x000b1;0.552</td></tr><tr><td align="left" rowspan="1" colspan="1">TYR-influx</td><td align="left" rowspan="1" colspan="1">ATD</td><td align="center" rowspan="1" colspan="1">5.647&#x000b1;0.297</td><td align="center" rowspan="1" colspan="1">2.997&#x000b1;0.167</td><td align="center" rowspan="1" colspan="1">3.002&#x000b1;0.173</td><td align="center" rowspan="1" colspan="1">3.139&#x000b1;0.173</td><td align="center" rowspan="1" colspan="1">2.911&#x000b1;0.189</td><td align="center" rowspan="1" colspan="1">3.514&#x000b1;0.266</td><td align="center" rowspan="1" colspan="1">4.078&#x000b1;0.311</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">BAL</td><td align="center" rowspan="1" colspan="1">5.338&#x000b1;0.297</td><td align="center" rowspan="1" colspan="1">2.054&#x000b1;0.167</td><td align="center" rowspan="1" colspan="1">1.866&#x000b1;0.173</td><td align="center" rowspan="1" colspan="1">1.877&#x000b1;0.173</td><td align="center" rowspan="1" colspan="1">1.921&#x000b1;0.189</td><td align="center" rowspan="1" colspan="1">1.959&#x000b1;0.266</td><td align="center" rowspan="1" colspan="1">2.523&#x000b1;0.311</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ATD<sub>PHE/LEU</sub>
</td><td align="center" rowspan="1" colspan="1">5.213&#x000b1;0.297</td><td align="center" rowspan="1" colspan="1">1.905&#x000b1;0.167</td><td align="center" rowspan="1" colspan="1">2.038&#x000b1;0.173</td><td align="center" rowspan="1" colspan="1">1.964&#x000b1;0.173</td><td align="center" rowspan="1" colspan="1">2.022&#x000b1;0.189</td><td align="center" rowspan="1" colspan="1">2.285&#x000b1;0.266</td><td align="center" rowspan="1" colspan="1">2.765&#x000b1;0.311</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">BAL<sub>PHE/LEU</sub>
</td><td align="center" rowspan="1" colspan="1">5.464&#x000b1;0.297</td><td align="center" rowspan="1" colspan="1">1.515&#x000b1;0.167</td><td align="center" rowspan="1" colspan="1">1.530&#x000b1;0.173</td><td align="center" rowspan="1" colspan="1">1.501&#x000b1;0.173</td><td align="center" rowspan="1" colspan="1">1.582&#x000b1;0.189</td><td align="center" rowspan="1" colspan="1">1.859&#x000b1;0.266</td><td align="center" rowspan="1" colspan="1">2.348&#x000b1;0.311</td></tr><tr><td align="left" rowspan="1" colspan="1">PHE-influx</td><td align="left" rowspan="1" colspan="1">ATD</td><td align="center" rowspan="1" colspan="1">10.391&#x000b1;0.630</td><td align="center" rowspan="1" colspan="1">18.342&#x000b1;0.628</td><td align="center" rowspan="1" colspan="1">19.733&#x000b1;0.918</td><td align="center" rowspan="1" colspan="1">18.719&#x000b1;0.981</td><td align="center" rowspan="1" colspan="1">19.493&#x000b1;1.120</td><td align="center" rowspan="1" colspan="1">18.008&#x000b1;1.219</td><td align="center" rowspan="1" colspan="1">16.975&#x000b1;1.119</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">BAL</td><td align="center" rowspan="1" colspan="1">10.819&#x000b1;0.630</td><td align="center" rowspan="1" colspan="1">14.706&#x000b1;0.628</td><td align="center" rowspan="1" colspan="1">16.091&#x000b1;0.918</td><td align="center" rowspan="1" colspan="1">14.764&#x000b1;0.981</td><td align="center" rowspan="1" colspan="1">14.540&#x000b1;1.120</td><td align="center" rowspan="1" colspan="1">14.522&#x000b1;1.219</td><td align="center" rowspan="1" colspan="1">14.088&#x000b1;1.119</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ATD<sub>PHE/LEU</sub>
</td><td align="center" rowspan="1" colspan="1">12.234&#x000b1;0.630</td><td align="center" rowspan="1" colspan="1">26.229&#x000b1;0.628</td><td align="center" rowspan="1" colspan="1">28.661&#x000b1;0.918</td><td align="center" rowspan="1" colspan="1">30.627&#x000b1;0.981</td><td align="center" rowspan="1" colspan="1">31.642&#x000b1;1.120</td><td align="center" rowspan="1" colspan="1">30.493&#x000b1;1.219</td><td align="center" rowspan="1" colspan="1">28.378&#x000b1;1.119</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">BAL<sub>PHE/LEU</sub>
</td><td align="center" rowspan="1" colspan="1">11.978&#x000b1;0.630</td><td align="center" rowspan="1" colspan="1">24.250&#x000b1;0.628</td><td align="center" rowspan="1" colspan="1">29.411&#x000b1;0.918</td><td align="center" rowspan="1" colspan="1">32.387&#x000b1;0.981</td><td align="center" rowspan="1" colspan="1">33.428&#x000b1;1.120</td><td align="center" rowspan="1" colspan="1">31.321&#x000b1;1.219</td><td align="center" rowspan="1" colspan="1">29.325&#x000b1;1.119</td></tr><tr><td align="left" rowspan="1" colspan="1">BCAA-influx</td><td align="left" rowspan="1" colspan="1">ATD</td><td align="center" rowspan="1" colspan="1">11.968&#x000b1;0.453</td><td align="center" rowspan="1" colspan="1">15.582&#x000b1;0.448</td><td align="center" rowspan="1" colspan="1">15.112&#x000b1;0.501</td><td align="center" rowspan="1" colspan="1">15.502&#x000b1;0.570</td><td align="center" rowspan="1" colspan="1">14.340&#x000b1;0.544</td><td align="center" rowspan="1" colspan="1">14.018&#x000b1;0.612</td><td align="center" rowspan="1" colspan="1">12.901&#x000b1;0.435</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">BAL</td><td align="center" rowspan="1" colspan="1">11.736&#x000b1;0.453</td><td align="center" rowspan="1" colspan="1">12.198&#x000b1;0.448</td><td align="center" rowspan="1" colspan="1">11.692&#x000b1;0.501</td><td align="center" rowspan="1" colspan="1">12.092&#x000b1;0.570</td><td align="center" rowspan="1" colspan="1">11.570&#x000b1;0.544</td><td align="center" rowspan="1" colspan="1">10.245&#x000b1;0.612</td><td align="center" rowspan="1" colspan="1">10.809&#x000b1;0.435</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ATD<sub>PHE/LEU</sub>
</td><td align="center" rowspan="1" colspan="1">10.937&#x000b1;0.453</td><td align="center" rowspan="1" colspan="1">8.505&#x000b1;0.448</td><td align="center" rowspan="1" colspan="1">7.131&#x000b1;0.501</td><td align="center" rowspan="1" colspan="1">6.524&#x000b1;0.570</td><td align="center" rowspan="1" colspan="1">5.587&#x000b1;0.544</td><td align="center" rowspan="1" colspan="1">4.464&#x000b1;0.612</td><td align="center" rowspan="1" colspan="1">3.872&#x000b1;0.435</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">BAL<sub>PHE/LEU</sub>
</td><td align="center" rowspan="1" colspan="1">10.814&#x000b1;0.453</td><td align="center" rowspan="1" colspan="1">7.352&#x000b1;0.448</td><td align="center" rowspan="1" colspan="1">6.171&#x000b1;0.501</td><td align="center" rowspan="1" colspan="1">5.968&#x000b1;0.570</td><td align="center" rowspan="1" colspan="1">5.044&#x000b1;0.544</td><td align="center" rowspan="1" colspan="1">3.958&#x000b1;0.612</td><td align="center" rowspan="1" colspan="1">3.164&#x000b1;0.435</td></tr></tbody></table><table-wrap-foot><fn><p>Calculated influx values (in nmol/min/g brain tissue) for tryptophan (TRP), tyrosine (TYR), phenylalanine (PHE), and branched-chain amino acids (BCAA; including valine, leucine, and isoleucine) across the blood-brain barrier after the administration of four different amino acid mixtures: ATD (acute tryptophan depletion; challenge condition), BAL (control condition for ATD), ATD<sub>PHE/LEU</sub> (newly developed challenge condition), and BAL<sub>PHE/LEU</sub> (control condition for ATD<sub>PHE/LEU</sub>). Mean values&#x000b1;standard error are presented for the different groups (each including 18 subjects) at the seven time points of blood withdrawal (T<sub>0</sub>&#x02013;T<sub>6</sub>).</p></fn></table-wrap-foot></table-wrap><sec id="S0003-S20001"><title>TRP influx into the brain</title><p>No significant differences in TRP influx were present at baseline (T<sub>0</sub>) when comparing ATD, BAL, ATD<sub>PHE/LEU</sub>, and BAL<sub>PHE/LEU</sub> (<italic>F</italic><sub>[3, 71]</sub>=2.005; <italic>p=n.s</italic>.). An rmANOVA yielded main effects of time (<italic>F</italic><sub>[3.801, 258.437]</sub>=69.972; <italic>p&#x0003c;</italic>0.001) and group (<italic>F</italic><sub>[3, 68]</sub>=97.577; <italic>p&#x0003c;</italic>0.001) and a significant time by group interaction (<italic>F</italic><sub>[11.402, 258.437]</sub>=25.875; <italic>p&#x0003c;</italic>0.001). Bonferroni <italic>post hoc</italic> analyses indicated significant differences between each of the four groups (mean TRP influx BAL&#x0003e;BAL<sub>PHE/LEU</sub>&#x0003e;ATD&#x0003e;ATD<sub>PHE/LEU</sub>; see <xref ref-type="supplementary-material" rid="S1">Supplementary Tables 2 and 3</xref> for detailed results). The comparison of the influx curves for all groups is given in <xref ref-type="fig" rid="F0001">Fig. 1</xref>a. Separate rmANOVAs with time as the within-subjects factor indicated a main effect of time for each group. <xref ref-type="table" rid="T0004">Table 4</xref> summarizes the degrees of freedom (df) and <italic>F</italic>- and <italic>p</italic>-values of these analyses. Time points of maximum TRP influx decline (T<sub>max</sub>), maximum decline in TRP influx in relation to baseline (Decline<sub>max</sub>), and overall TRP influx declines from baseline to time point T<sub>6</sub> for each group are given in <xref ref-type="table" rid="T0005">Table 5</xref>. Maximum decrease in TRP influx 4 h after intake was 11.9% higher for ATD<sub>PHE/LEU</sub> compared with the decrease found for ATD. In contrast to ATD, ATD<sub>PHE/LEU</sub>, and BAL<sub>PHE/LEU</sub> administration, a significant increase in TRP influx was detected in the BAL condition control group during the first 60 min after beverage administration (<italic>p</italic>=0.002), while no significant changes in influx rates were detected over the entire period from T<sub>0</sub> to T<sub>6</sub>. No effect of gender was detected (<italic>F</italic><sub>[1, 67]</sub>=2.537; <italic>p</italic>=n.s.). <italic>Post hoc</italic> power analysis showed that our study was adequately powered (power of 0.95) to detect effect sizes of 0.25 with an alpha level of 0.05 using a between-subjects repeated measures approach (ANOVA). In addition, we calculated Cohen's <italic>d</italic>-values as an estimate for effect sizes (<italic>d</italic>-value of <italic>d</italic>=0.24 for the comparison of TRP-influx after ATD versus BAL administration; <italic>d</italic>=0.14 for the comparison of ATD<sub>PHE/LEU</sub> and BAL<sub>PHE/LEU</sub>).</p><fig id="F0001" position="float"><label>Fig. 1</label><caption><p>(a, b, c) Influx curves (nmol/min/g brain tissue) of tryptophan (TRP), tyrosine, and phenylalanine across the blood-brain barrier at baseline (T0) and time points T1&#x02013;T6 after the intake of the ATD Moja-De amino acid (AA) mixture, its balanced control condition (BAL), the newly developed tryptophan depletion protocol ATD<sub>PHE/LEU</sub>, and the corresponding control condition (BAL<sub>PHE/LEU</sub>). Data are given as the mean values, with bars representing the standard errors.</p></caption><graphic xlink:href="FNR-60-29272-g001"/></fig><table-wrap id="T0004" position="float"><label>Table 4</label><caption><p>Results of rmANOVA on tryptophan influx values</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">ATD</th><th align="center" rowspan="1" colspan="1">BAL</th><th align="center" rowspan="1" colspan="1">ATD<sub>PHE/LEU</sub></th><th align="center" rowspan="1" colspan="1">BAL<sub>PHE/LEU</sub></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">df</td><td align="center" rowspan="1" colspan="1">2.130, 36.206</td><td align="center" rowspan="1" colspan="1">3.136, 53.314</td><td align="center" rowspan="1" colspan="1">1.269, 21.579</td><td align="center" rowspan="1" colspan="1">4.057, 68.962</td></tr><tr><td align="left" rowspan="1" colspan="1">F</td><td align="center" rowspan="1" colspan="1">86.110</td><td align="center" rowspan="1" colspan="1">7.646</td><td align="center" rowspan="1" colspan="1">120.067</td><td align="center" rowspan="1" colspan="1">20.645</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>p</italic></td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><fn><p>Results of separate repeated measurements analyses of variance (rmANOVAs) on tryptophan (TRP) influx across the blood-brain barrier for ATD (challenge condition), BAL (control condition for ATD), ATD<sub>PHE/LEU</sub> (newly developed challenge condition), and BAL<sub>PHE/LEU</sub> (control condition for ATD<sub>PHE/LEU</sub>), with time as the within-subjects factor. df, degrees of freedom; <italic>F</italic>, <italic>F</italic> values; <italic>p</italic>, statistical significance.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T0005" position="float"><label>Table 5</label><caption><p>Descriptive data of tryptophan depletion graphs</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">ATD</th><th align="center" rowspan="1" colspan="1">BAL</th><th align="center" rowspan="1" colspan="1">ATD<sub>PHE/LEU</sub>
</th><th align="center" rowspan="1" colspan="1">BAL<sub>PHE/LEU</sub>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">T<sub>max</sub> (min)</td><td align="center" rowspan="1" colspan="1">240</td><td align="center" rowspan="1" colspan="1">60</td><td align="center" rowspan="1" colspan="1">240</td><td align="center" rowspan="1" colspan="1">360</td></tr><tr><td align="left" rowspan="1" colspan="1">Decline<sub>max</sub> (%)</td><td align="center" rowspan="1" colspan="1">63.9</td><td align="center" rowspan="1" colspan="1">29.1 (increase)</td><td align="center" rowspan="1" colspan="1">75.8</td><td align="center" rowspan="1" colspan="1">34.4</td></tr><tr><td align="left" rowspan="1" colspan="1">Decline<sub>T0-T6</sub> (%)</td><td align="center" rowspan="1" colspan="1">52.5</td><td align="center" rowspan="1" colspan="1">6.9 (increase)</td><td align="center" rowspan="1" colspan="1">70.7</td><td align="center" rowspan="1" colspan="1">34.4</td></tr></tbody></table><table-wrap-foot><fn><p>Time points of maximum tryptophan (TRP) influx decline (T<sub>max</sub>), maximum declines of TRP influx in relation to baseline (T<sub>0</sub>) (Decline<sub>max</sub>), and overall TRP influx declines from baseline (T<sub>0</sub>) to time point T<sub>6</sub> (time point of last blood sample) for the groups ATD (challenge condition), BAL (control condition for ATD), ATD<sub>PHE/LEU</sub> (newly developed challenge condition), and BAL<sub>PHE/LEU</sub> (control condition for ATD<sub>PHE/LEU</sub>).</p></fn></table-wrap-foot></table-wrap></sec><sec id="S0003-S20002"><title>TYR and PHE influx into the brain</title><p>An rmANOVA on TYR influx rates indicated main effects of time (<italic>F</italic><sub>[2.122, 144.270]</sub>=226.885; <italic>p</italic>&#x0003c;0.001) and group (<italic>F</italic><sub>[3, 68]</sub>=11.191; <italic>p</italic>&#x0003c;0.001) and a significant time by group interaction (<italic>F</italic><sub>[6.365, 144.270]</sub>=2.255; <italic>p</italic>=0.038). Bonferroni <italic>post hoc</italic> analyses indicated that only ATD showed significant difference from the other three treatment conditions, while no significant difference could be found between the three of them. With regard to TYR influx, the curve progression for all treatment conditions was overall comparable with a strong decrease in TYR influx during the first hour (see <xref ref-type="fig" rid="F0001">Fig. 1</xref>b). While TYR influx after ATD administration was maximally decreased by 48% of the baseline value, influx after ATD<sub>PHE/LEU</sub> displayed a decrease of 71%. Similar analyses for PHE influx values also showed main effects of time (<italic>F</italic><sub>[3.849, 261.745]</sub>=204.575; <italic>p</italic>&#x0003c;0.001) and group (<italic>F</italic><sub>[3, 68]</sub>=77.348; <italic>p</italic>&#x0003c;0.001) and a significant time by group interaction (<italic>F</italic><sub>[11.548, 261.745]</sub>=2.255; <italic>p</italic>&#x0003c;0.001). Bonferroni <italic>post hoc</italic> analyses indicated significant differences between all groups, except of ATD<sub>PHE/LEU</sub> versus BAL<sub>PHE/LEU</sub> that did not present any significant results. PHE influx curves for all groups can be found in <xref ref-type="fig" rid="F0001">Fig. 1</xref>c. For ATD<sub>PHE/LEU</sub> and BAL<sub>PHE/LEU,</sub> PHE influx values showed an increase during the first 4 h, followed by only a small decrease until T<sub>6</sub> (ATD<sub>PHE/LEU</sub>: maximum increase by 159% of baseline; BAL<sub>PHE/LEU</sub>: maximum increase by 179% of baseline). In comparison, a much smaller increase of PHE influx appeared after ATD (maximum increase by 89% of baseline) and BAL (increase by 49% of baseline) administration.</p></sec><sec id="S0003-S20003"><title>[TRP]/[CAA]</title><p><xref ref-type="fig" rid="F0002">Figure 2</xref> shows the time course of [TRP]/[CAA] ratios for the four treatment conditions, which offers a comparable development with regard to TRP influx calculations, but with a focus on plasma concentrations. No significant differences in the ratios were present at baseline (T<sub>0</sub>) when comparing ATD, BAL, ATD<sub>PHE/LEU</sub>, and BAL<sub>PHE/LEU</sub> (<italic>F</italic><sub>[3, 71]</sub>=0.898; <italic>p</italic>=n.s.). An rmANOVA yielded main effects of time (<italic>F</italic><sub>[4.213, 286.489]</sub>=5.447; <italic>p</italic>&#x0003c;0.001) and group (<italic>F</italic><sub>[3, 68]</sub>=73.368; <italic>p</italic>&#x0003c;0.001) and a significant time by group interaction (<italic>F</italic><sub>[12.639, 286.489]</sub>=17.960; <italic>p</italic>&#x0003c;0.001). Bonferroni <italic>post hoc</italic> analyses indicated significant differences between each of the four groups except of no significant result for ATD and ATD<sub>PHE/LEU</sub>. Maximum decrease in [TRP]/[CAA] ratio is reached 4 h after intake (T<sub>4</sub>) for both protocols. ATD and ATD<sub>PHE/LEU</sub> reduced the ratio by 66 and 65%, respectively, when compared with baseline. Values of all calculated ratios are given in <xref ref-type="table" rid="T0006">Table 6</xref>, and additional graphs for [TYR]/[CAA] and [PHE]/[CAA] ratios of all groups are presented in <xref ref-type="supplementary-material" rid="S1">Supplementary Fig. S1a and S1b</xref>.</p><fig id="F0002" position="float"><label>Fig. 2</label><caption><p>Curve progression for calculated TRP/CAA ratios from baseline (T0) to time point T6 after the intake of the ATD Moja-De amino acid (AA) mixture, its balanced control condition (BAL), the newly developed tryptophan depletion protocol ATD<sub>PHE/LEU</sub>, and the corresponding control condition (BAL<sub>PHE/LEU</sub>). Data are given as the mean values, with bars representing the standard errors.</p></caption><graphic xlink:href="FNR-60-29272-g002"/></fig><table-wrap id="T0006" position="float"><label>Table 6</label><caption><p>Amino acid ratios</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Parameter</th><th align="center" rowspan="1" colspan="1">Mixture</th><th align="center" rowspan="1" colspan="1">Baseline (T<sub>0</sub>)</th><th align="center" rowspan="1" colspan="1">T<sub>1</sub></th><th align="center" rowspan="1" colspan="1">T<sub>2</sub></th><th align="center" rowspan="1" colspan="1">T<sub>3</sub></th><th align="center" rowspan="1" colspan="1">T<sub>4</sub></th><th align="center" rowspan="1" colspan="1">T<sub>5</sub></th><th align="center" rowspan="1" colspan="1">T<sub>6</sub></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">[TRP]/[CAA]</td><td align="left" rowspan="1" colspan="1">ATD</td><td align="center" rowspan="1" colspan="1">0.134&#x000b1;0.006</td><td align="center" rowspan="1" colspan="1">0.063&#x000b1;0.013</td><td align="center" rowspan="1" colspan="1">0.055&#x000b1;0.012</td><td align="center" rowspan="1" colspan="1">0.051&#x000b1;0.014</td><td align="center" rowspan="1" colspan="1">0.046&#x000b1;0.014</td><td align="center" rowspan="1" colspan="1">0.049&#x000b1;0.014</td><td align="center" rowspan="1" colspan="1">0.057&#x000b1;0.010</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">BAL</td><td align="center" rowspan="1" colspan="1">0.135&#x000b1;0.006</td><td align="center" rowspan="1" colspan="1">0.251&#x000b1;0.013</td><td align="center" rowspan="1" colspan="1">0.248&#x000b1;0.012</td><td align="center" rowspan="1" colspan="1">0.247&#x000b1;0.014</td><td align="center" rowspan="1" colspan="1">0.253&#x000b1;0.014</td><td align="center" rowspan="1" colspan="1">0.204&#x000b1;0.014</td><td align="center" rowspan="1" colspan="1">0.186&#x000b1;0.010</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ATD<sub>PHE/LEU</sub></td><td align="center" rowspan="1" colspan="1">0.123&#x000b1;0.006</td><td align="center" rowspan="1" colspan="1">0.050&#x000b1;0.013</td><td align="center" rowspan="1" colspan="1">0.047&#x000b1;0.012</td><td align="center" rowspan="1" colspan="1">0.044&#x000b1;0.014</td><td align="center" rowspan="1" colspan="1">0.043&#x000b1;0.014</td><td align="center" rowspan="1" colspan="1">0.0493&#x000b1;0.014</td><td align="center" rowspan="1" colspan="1">0.057&#x000b1;0.010</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">BAL<sub>PHE/LEU</sub></td><td align="center" rowspan="1" colspan="1">0.129&#x000b1;0.006</td><td align="center" rowspan="1" colspan="1">0.225&#x000b1;0.013</td><td align="center" rowspan="1" colspan="1">0.168&#x000b1;0.012</td><td align="center" rowspan="1" colspan="1">0.158&#x000b1;0.014</td><td align="center" rowspan="1" colspan="1">0.155&#x000b1;0.014</td><td align="center" rowspan="1" colspan="1">0.172&#x000b1;0.014</td><td align="center" rowspan="1" colspan="1">0.162&#x000b1;0.010</td></tr><tr><td align="left" rowspan="1" colspan="1">[PHE]/[CAA]</td><td align="left" rowspan="1" colspan="1">ATD</td><td align="center" rowspan="1" colspan="1">0.094&#x000b1;0.043</td><td align="center" rowspan="1" colspan="1">0.232&#x000b1;0.037</td><td align="center" rowspan="1" colspan="1">0.320&#x000b1;0.078</td><td align="center" rowspan="1" colspan="1">0.293&#x000b1;0.077</td><td align="center" rowspan="1" colspan="1">0.329&#x000b1;0.087</td><td align="center" rowspan="1" colspan="1">0.308&#x000b1;0.117</td><td align="center" rowspan="1" colspan="1">0.254&#x000b1;0.139</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">BAL</td><td align="center" rowspan="1" colspan="1">0.102&#x000b1;0.043</td><td align="center" rowspan="1" colspan="1">0.182&#x000b1;0.037</td><td align="center" rowspan="1" colspan="1">0.220&#x000b1;0.078</td><td align="center" rowspan="1" colspan="1">0.193&#x000b1;0.077</td><td align="center" rowspan="1" colspan="1">0.193&#x000b1;0.087</td><td align="center" rowspan="1" colspan="1">0.213&#x000b1;0.117</td><td align="center" rowspan="1" colspan="1">0.191&#x000b1;0.139</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ATD<sub>PHE/LEU</sub></td><td align="center" rowspan="1" colspan="1">0.206&#x000b1;0.043</td><td align="center" rowspan="1" colspan="1">0.759&#x000b1;0.037</td><td align="center" rowspan="1" colspan="1">1.039&#x000b1;0.078</td><td align="center" rowspan="1" colspan="1">1.183&#x000b1;0.077</td><td align="center" rowspan="1" colspan="1">1.399&#x000b1;0.087</td><td align="center" rowspan="1" colspan="1">1.548&#x000b1;0.117</td><td align="center" rowspan="1" colspan="1">1.561&#x000b1;0.139</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">BAL<sub>PHE/LEU</sub></td><td align="center" rowspan="1" colspan="1">0.163&#x000b1;0.043</td><td align="center" rowspan="1" colspan="1">0.610&#x000b1;0.037</td><td align="center" rowspan="1" colspan="1">0.952&#x000b1;0.078</td><td align="center" rowspan="1" colspan="1">1.155&#x000b1;0.077</td><td align="center" rowspan="1" colspan="1">1.334&#x000b1;0.087</td><td align="center" rowspan="1" colspan="1">1.403&#x000b1;0.117</td><td align="center" rowspan="1" colspan="1">1.462&#x000b1;0.139</td></tr><tr><td align="left" rowspan="1" colspan="1">[TYR]/[CAA]</td><td align="left" rowspan="1" colspan="1">ATD</td><td align="center" rowspan="1" colspan="1">0.108&#x000b1;0.006</td><td align="center" rowspan="1" colspan="1">0.056&#x000b1;0.004</td><td align="center" rowspan="1" colspan="1">0.059&#x000b1;0.004</td><td align="center" rowspan="1" colspan="1">0.059&#x000b1;0.005</td><td align="center" rowspan="1" colspan="1">0.059&#x000b1;0.006</td><td align="center" rowspan="1" colspan="1">0.068&#x000b1;0.009</td><td align="center" rowspan="1" colspan="1">0.081&#x000b1;0.012</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">BAL</td><td align="center" rowspan="1" colspan="1">0.103&#x000b1;0.006</td><td align="center" rowspan="1" colspan="1">0.048&#x000b1;0.004</td><td align="center" rowspan="1" colspan="1">0.046&#x000b1;0.004</td><td align="center" rowspan="1" colspan="1">0.043&#x000b1;0.005</td><td align="center" rowspan="1" colspan="1">0.045&#x000b1;0.006</td><td align="center" rowspan="1" colspan="1">0.047&#x000b1;0.009</td><td align="center" rowspan="1" colspan="1">0.056&#x000b1;0.012</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ATD<sub>PHE/LEU</sub></td><td align="center" rowspan="1" colspan="1">0.105&#x000b1;0.006</td><td align="center" rowspan="1" colspan="1">0.063&#x000b1;0.004</td><td align="center" rowspan="1" colspan="1">0.075&#x000b1;0.004</td><td align="center" rowspan="1" colspan="1">0.079&#x000b1;0.005</td><td align="center" rowspan="1" colspan="1">0.086&#x000b1;0.006</td><td align="center" rowspan="1" colspan="1">0.103&#x000b1;0.009</td><td align="center" rowspan="1" colspan="1">0.124&#x000b1;0.012</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">BAL<sub>PHE/LEU</sub></td><td align="center" rowspan="1" colspan="1">0.112&#x000b1;0.006</td><td align="center" rowspan="1" colspan="1">0.054&#x000b1;0.004</td><td align="center" rowspan="1" colspan="1">0.062&#x000b1;0.004</td><td align="center" rowspan="1" colspan="1">0.063&#x000b1;0.005</td><td align="center" rowspan="1" colspan="1">0.070&#x000b1;0.006</td><td align="center" rowspan="1" colspan="1">0.085&#x000b1;0.009</td><td align="center" rowspan="1" colspan="1">0.112&#x000b1;0.012</td></tr><tr><td align="left" rowspan="1" colspan="1">[PHE+TYR]/</td><td align="left" rowspan="1" colspan="1">ATD</td><td align="center" rowspan="1" colspan="1">0.226&#x000b1;0.051</td><td align="center" rowspan="1" colspan="1">0.318&#x000b1;0.043</td><td align="center" rowspan="1" colspan="1">0.428&#x000b1;0.093</td><td align="center" rowspan="1" colspan="1">0.405&#x000b1;0.093</td><td align="center" rowspan="1" colspan="1">0.447&#x000b1;0.103</td><td align="center" rowspan="1" colspan="1">0.451&#x000b1;0.145</td><td align="center" rowspan="1" colspan="1">0.395&#x000b1;0.194</td></tr><tr><td align="left" rowspan="1" colspan="1">[BCAA+TRP]</td><td align="left" rowspan="1" colspan="1">BAL</td><td align="center" rowspan="1" colspan="1">0.229&#x000b1;0.051</td><td align="center" rowspan="1" colspan="1">0.250&#x000b1;0.043</td><td align="center" rowspan="1" colspan="1">0.289&#x000b1;0.093</td><td align="center" rowspan="1" colspan="1">0.255&#x000b1;0.093</td><td align="center" rowspan="1" colspan="1">0.257&#x000b1;0.103</td><td align="center" rowspan="1" colspan="1">0.285&#x000b1;0.145</td><td align="center" rowspan="1" colspan="1">0.270&#x000b1;0.194</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ATD<sub>PHE/LEU</sub></td><td align="center" rowspan="1" colspan="1">0.359&#x000b1;0.051</td><td align="center" rowspan="1" colspan="1">0.963&#x000b1;0.043</td><td align="center" rowspan="1" colspan="1">1.373&#x000b1;0.093</td><td align="center" rowspan="1" colspan="1">1.594&#x000b1;0.093</td><td align="center" rowspan="1" colspan="1">1.927&#x000b1;0.103</td><td align="center" rowspan="1" colspan="1">2.268&#x000b1;0.145</td><td align="center" rowspan="1" colspan="1">2.450&#x000b1;0.194</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">BAL<sub>PHE/LEU</sub></td><td align="center" rowspan="1" colspan="1">0.313&#x000b1;0.051</td><td align="center" rowspan="1" colspan="1">0.756&#x000b1;0.043</td><td align="center" rowspan="1" colspan="1">1.188&#x000b1;0.093</td><td align="center" rowspan="1" colspan="1">1.452&#x000b1;0.093</td><td align="center" rowspan="1" colspan="1">1.723&#x000b1;0.103</td><td align="center" rowspan="1" colspan="1">1.882&#x000b1;0.145</td><td align="center" rowspan="1" colspan="1">2.096&#x000b1;0.194</td></tr></tbody></table><table-wrap-foot><fn><p>Ratios of tryptophan, phenylalanine, tyrosine, and branched-chain amino acids (BCAA; including valine, leucine, and isoleucine) and their competing amino acids (CAA) after the administration of four different amino acid mixtures: ATD (acute tryptophan depletion; challenge condition), BAL (control condition for ATD), ATD<sub>PHE/LEU</sub> (newly developed challenge condition), and BAL<sub>PHE/LEU</sub> (control condition for ATD<sub>PHE/LEU</sub>). Mean values&#x000b1;standard error are given for the different groups (each including 18 subjects) at the seven time points of blood withdrawal (T0&#x02013;T6).</p></fn></table-wrap-foot></table-wrap></sec><sec id="S0003-S20004"><title>Taste</title><p>One-way ANOVA of the taste evaluation scores with gender as a covariate yielded no significant difference in taste perceptions between the groups (<italic>F</italic><sub>[3, 67]</sub>=0.997; <italic>p=</italic>n.s.) and no effect of gender (<italic>F</italic><sub>[1, 67]</sub>=0.102; <italic>p</italic>=n.s.).</p></sec><sec id="S0003-S20005"><title>Challenge tolerance</title><p>An rmANOVA evaluation of challenge tolerance indicated a main effect of time for the analysis of the hunger score (<italic>F</italic><sub>[4.760, 314.190]</sub>=4.457; <italic>p=</italic>0.001); <italic>post hoc</italic> testing indicated a significant increase in hunger from baseline (T<sub>0</sub>) to T<sub>6</sub> (<italic>p</italic>=0.001). Similar analyses of the awakeness score also yielded a main effect of time (<italic>F</italic><sub>[4.182, 275.991]</sub>=9.741; <italic>p&#x0003c;</italic>0.001). Within the 6 h from baseline (T<sub>0</sub>) to T<sub>6</sub>, the awakeness score decreased significantly (<italic>p</italic>=0.001), but participants felt most tired at T<sub>2</sub>. The main effects of time (<italic>F</italic><sub>[4.018, 265.208]</sub>=5.077; <italic>p=</italic>0.001) and group (<italic>F</italic><sub>[3, 66]</sub>=3.939; <italic>p=</italic>0.012) were detected for the somatic complaints score and indicated an increase in somatic complaints over time. Bonferroni <italic>post hoc</italic> analyses showed a significant difference between BAL<sub>PHE/LEU</sub> and BAL administration (<italic>p=</italic>0.012). The average somatic complaints score related to BAL<sub>PHE/LEU</sub> administration (average score 0.708&#x000b1;0.117) was four times greater than the values reported by the BAL condition group (average score 0.169&#x000b1;0.121). While the participants overall felt more unwell 2 h (T<sub>2</sub>) after the intake of the AA mixtures (<italic>p</italic>=0.022), the somatic complaints scores decreased from T<sub>2</sub> to T<sub>4</sub> (<italic>p</italic>=0.002), with only a slight, non-significant increase observed at T<sub>6</sub> compared with the baseline score. At baseline, there were no significant differences in somatic complaints scores between the groups (<italic>F</italic><sub>[3, 68]</sub>=0.169; <italic>p=</italic>n.s.). Analyses of each individual item in the somatic complaints score showed a comparable development of nausea. The report of nausea significantly increased from T<sub>0</sub> to T<sub>2</sub> (<italic>p</italic>=0.046) and then significantly decreased from T<sub>2</sub> to T<sub>4</sub> (<italic>p</italic>=0.014). No gender effects were detected in the hunger (<italic>F</italic><sub>[1, 65]</sub>=0.192; <italic>p=</italic>n.s.), awakeness (<italic>F</italic><sub>[1, 65]</sub>=0.769; <italic>p=</italic>n.s.), or somatic complaints scores (<italic>F</italic><sub>[1, 65]</sub>=0.179; <italic>p=</italic>n.s.).</p></sec><sec id="S0003-S20006"><title>Mood assessment (PANAS)</title><p>An rmANOVA of the PA score showed a main effect of time (<italic>F</italic><sub>[3.335, 220.091]</sub>=54.110; <italic>p&#x0003c;</italic>0.001), but no significant effect of group (<italic>F</italic><sub>[3, 65]</sub>=0.215; <italic>p=</italic>n.s.) or gender (<italic>F</italic><sub>[1, 65]</sub>=0.933; <italic>p=</italic>n.s.). Compared with the baseline score, a decrease in the PA score of 28.5% at T<sub>6</sub> was observed (<italic>p</italic>&#x0003c;0.001). The NA score also decreased (11.4% from baseline to T6; <italic>F</italic><sub>[3.198, 211.086]</sub>=12.502; <italic>p&#x0003c;</italic>0.001, rmANOVA) regardless of gender (<italic>F</italic><sub>[1, 65]</sub>=0.268; <italic>p=</italic>n.s.).</p></sec></sec><sec sec-type="discussion" id="S0004"><title>Discussion</title><p>The results of this pilot study indicate that dietary administration of ATD<sub>PHE/LEU</sub> led to a greater depletion magnitude with regard to the TRP influx across the BBB compared with the depletion observed when using the ATD Moja-De protocol, but not with regard to plasma TRP concentrations because of an unintended initial short increase in plasma TRP concentrations that was observed after ATD<sub>PHE/LEU</sub> intake (see further below in this section for a discussion). The found effect on TRP influx across the BBB was observed even though ATD<sub>PHE/LEU</sub>, which consisted of only two AAs (PHE and LEU), was administered in a lower overall AA dose. Participants evaluated the tolerance level of the new AA challenge beverage as acceptable. No situations or events necessitating premature termination of the study occurred (such as participants vomiting during measurements or other incidents affecting ratings). Thus, several criteria for a potentially valid and effective ATD-test protocol were already achieved, while other aspects such as the observed unexpected increase in plasma TRP levels require further improvements and future studies in order to validate the findings of the current pilot study.</p><p>The altered composition of ATD<sub>PHE/LEU</sub>, including only two AAs, in contrast to the ATD Moja-De that includes seven different AAs, should lead to a greatly simplified production of the AA beverage. Moreover, it also enables facilitated monitoring of relevant blood parameters (i.e. AA concentrations) as their number was consequently reduced. Such monitoring was further simplified by the development and use of ELISA and BCAA test kits (Immundiagnostik AG, Bensheim, Germany). ATD<sub>PHE/LEU</sub> uses the same body weight-adapted dosing regimen of the ATD AA mixtures that was first successfully applied in the ATD Moja-De protocol (<xref rid="CIT0036" ref-type="bibr">36</xref>, <xref rid="CIT0037" ref-type="bibr">37</xref>). This well-tolerated dosing regimen is based on the assumption of a positive correlation between body weight and plasma TRP levels (<xref rid="CIT0036" ref-type="bibr">36</xref>, <xref rid="CIT0037" ref-type="bibr">37</xref>) and, as a significant advantage, leads to a possible application for children and adolescents with fewer side effects (<xref rid="CIT0042" ref-type="bibr">42</xref>&#x02013;<xref rid="CIT0044" ref-type="bibr">44</xref>, <xref rid="CIT0049" ref-type="bibr">49</xref>, <xref rid="CIT0050" ref-type="bibr">50</xref>).</p><p>The greater effectiveness of ATD<sub>PHE/LEU</sub> in terms of a greater reduction in TRP influx across the BBB when compared with ATD Moja-De could be seen as an advantage, whereas the found effects on plasma TRP concentrations require further investigation. The reason for the detected effects on TRP influx into the brain may lie in the different affinities of the LNAAs to the common L-1 transporter. The Michaelis constant (K<sub>M</sub>) represents a measurement of these particular affinities. Precisely, it is indicative of the specific substrate concentration needed to achieve the half-maximal rate of turnover of an enzyme. Thus, a lower K<sub>M</sub> value of a substrate is associated with its higher affinity to the related enzyme. Smith et al. (<xref rid="CIT0016" ref-type="bibr">16</xref>) determined the values of transport constants for seven LNAAs, including PHE (0.011 &#x000b5;mol&#x000b7;ml<sup>&#x02212;1</sup>) and LEU (0.029 &#x000b5;mol&#x000b7;ml<sup>&#x02212;1</sup>), in anesthetized rats. It must be acknowledged that transferring findings from rodent research to humans is subject to limitations. However, these values for the respective transport constants can serve as a first rough estimate, and the high and significant positive correlations between TRP influx and the TRP/CAA ratio (a previous measure for the effects of ATD) are consistent with the theoretical considerations for using Michaelis&#x02013;Menten kinetics to characterize TRP influx across the BBB. The high affinity of PHE and LEU to L-1, compared with all other LNAAs, may have caused the best displacement of TRP at the common transporter and therefore was possibly associated with a greater reduction of TRP influx across the BBB. By contrast, the ATD Moja-De, containing a mixture of seven different AAs with partly lower K<sub>M</sub> values, was less effective with regard to the competition of the AAs against TRP, resulting in a smaller TRP depletion magnitude in terms of TRP influx across the BBB compared with the ATD<sub>PHE/LEU</sub> depletion magnitude. It is possible that the use of this competitive mechanism in the respective AAs enables the potential effectiveness of TRP depletion after ATD<sub>PHE/LEU</sub> administration, despite the simultaneous reduction in the overall AA dose and thus a possibly decreased stimulation of protein synthesis in the liver when compared to other ATD protocols. This could have impacted the observed findings with regard to changes in plasma TRP concentrations and a possible redistribution between free and protein-bound TRP. The observed TRP influx curves of the old and new challenge protocols over the entire study duration resulted in maximum depletion in terms of decreased TRP influx across the BBB at 4 h after intake for both challenge procedures. In particular, TRP influx correlated highly and significantly with the TRP/CAA ratio for both ATD challenge conditions used (see <xref ref-type="supplementary-material" rid="S1">Supplementary Tables S5 and S6</xref> and <xref ref-type="supplementary-material" rid="S1">Fig. S2a and S2b</xref>), but the influx rates are likely to be a more adequate reflection of TRP availability in the brain as they also take the individual affinities of the different amino acids to the L-1 transport system at the BBB into account.</p><p>It is important to keep in mind that this work only claims to be a first pilot study. Therefore, the assessment of brain TRP and 5-HT concentrations after ATD<sub>PHE/LEU</sub> application in rodents has to be an essential part of future research as well as PET-studies and the measurement of 5-hydroxyindoleacetic acid (5-HIAA) concentrations (the primary metabolite of 5-HT) in human cerebrospinal fluid in order to validate the effectiveness of ATD<sub>PHE/LEU</sub> revealed by this study. A recent study by S&#x000e1;nchez et al. (<xref rid="CIT0012" ref-type="bibr">12</xref>) has provided preliminary evidence for the effectiveness of simplified ATD protocols using a three-AA-formulation (PHE, LEU, and ILE); however, future studies in humans assessing cerebrospinal fluid (CSF) 5-HIAA concentrations after intake of the challenge procedure are needed.</p><p>The absence of any gender effects in the blood parameters was an expected outcome. Although central nervous 5-HT synthesis is known to significantly differ in males and females (<xref rid="CIT0051" ref-type="bibr">51</xref>), we monitored peripheral TRP and LNAA plasma levels for TRP influx calculations; these parameters are not influenced by gender-specific alterations in TRP influx and related central nervous 5-HT synthesis. The performed power analyses confirmed that this study was adequately powered to detect small effects, and Cohen's d calculations indicated small estimates for effect sizes for the analyses conducted.</p><p>Specificity for depleting central nervous 5-HT synthesis (in particular with regard to possible effects on dopamine and other neurotransmitters) is always an important point to be considered with regard to all available ATD-related amino acid formulations. Previous research from our group indicated that the Moja-De protocol does not affect central nervous dopamine synthesis in mice (<xref rid="CIT0038" ref-type="bibr">38</xref>). As such evidence is currently missing for the newly developed protocol ATD<sub>PHE/LEU</sub>, we looked at TYR and PHE plasma values and their calculated influx into the brain. The strong decrease in TYR influx after challenge application, as described above, questions the specificity of the newly developed ATD<sub>PHE/LEU</sub> condition. The phenomenon of highly increasing PHE influx values in the ATD<sub>PHE/LEU</sub> protocol group can be explained by its high PHE concentrations. As the strong decrease in TYR influx indicates, the high PHE dose does not mitigate the decrease in TYR influx (calculated from peripheral blood values). Whether the high PHE amount in the ATD<sub>PHE/LEU</sub> mixture directly affects central nervous concentrations of TYR formation can only be answered using future neurochemical challenge studies. However, specificity for respective neurotransmitters is always a critical issue when dealing with different TRP depletion protocols. This is a general problem in ATD-related research in humans and affects all currently available ATD amino acid formulations. Badawy et al. (<xref rid="CIT0052" ref-type="bibr">52</xref>) provided an approach to enhance ATD formulations&#x02019; specificity by decreasing the amount of BCAAs. In accordance with this, the reduction of the LEU amount in our newly developed ATD<sub>PHE/LEU</sub> protocol might be a potential avenue for future research. An unintended rather substantial increase in plasma TRP was observed after ATD<sub>PHE/LEU</sub> intake besides the fact that no TRP was ingested, and future studies are needed to investigate and replicate this unknown effect. Protein synthesis can be stimulated by the ingested amino acids, which in turn might have led to a possible redistribution between free and protein-bound TRP. Following this train of thought, the amount of free TRP possibly was slightly higher while the overall balance remained unaffected. It also needs to be outlined that TRP-related metabolites, such as quinolinic acid, kynurenic acid, and tryptamine that can be changed due to administration of the balanced mixture, can influence brain function. This stands in line with the issue of the specificity of all ATD/BAL paradigms currently available. Finally, the reason why the fasting TRP levels (T0) were higher than those mentioned in the literature is not clear but worth noting and might be specific to the investigated sample.</p><p>Another issue regarding our new ATD challenge protocol is the absence of an appropriate control condition that &#x02018;maintains baseline values without altering the biochemical or behavioral parameters&#x02019; (<xref rid="CIT0052" ref-type="bibr">52</xref>). The observed rise in TRP influx approximately 1 h after administration of the BAL control condition seems to be a logical consequence of the enhanced TRP availability because the BAL mixture contained TRP. For this particular reason, the decline in TRP influx of 34.4% after BAL<sub>PHE/LEU</sub> administration over the 6-h period appears to be counterintuitive. When comparing BAL<sub>PHE/LEU</sub> with its challenge condition ATD<sub>PHE/LEU</sub>, the administration of BAL<sub>PHE/LEU</sub> led to a depletion of approximately 50% in magnitude of the depletion observed following ATD<sub>PHE/LEU</sub> administration. The large amount of PHE in the BAL<sub>PHE/LEU</sub> mixture may be a possible explanation for this particular phenomenon, which in turn could lead to an unexpected increase in displacement of TRP at the BBB in this control condition. To address this particular problem, either an increase in TRP or decreased levels of PHE or LEU in the control condition could be evaluated in future research in order to establish a valid control condition for ATD<sub>PHE/LEU</sub>.</p><p>Both protocols that were applied in this study, ATD and BAL on the one hand and ATD<sub>PHE/LEU</sub> and BAL<sub>PHE/LEU</sub> on the other hand, were well tolerated by the subjects. In particular, we did not observe any headaches, vomiting, dizziness, or sweating as indicated by the itemizing analyses of our somatic complaints score (see <xref ref-type="supplementary-material" rid="S1">Supplementary Table S3</xref>). There were no dropouts caused by side effects. Hence, this requirement of a valid test protocol was met. Although we could not observe a significant group effect for the somatic complaints score between ATD and ATD<sub>PHE/LEU</sub> indicating a reduction of side effects in the new challenge condition, we achieved the goal of maintaining the high-grade safety of the established ATD Moja-De.</p><p>The monitored increase in hunger throughout the study day most likely resulted from the 6-h abstinence from food and a breakfast overall low in nutrition. The lack of any group effect in hunger ratings supports the previous assumption. This observation justifies the necessity of the low-protein breakfast at the beginning of the study day. However, although its carbohydrate content can, to some extent, affect plasma TRP concentration and binding and levels of BCAA, it would not be justifiable to demand fasting beginning at 8 p.m. the night before the study day till 3 p.m. on the study day. Furthermore, the collection of additional behavioral, cognitive, and emotional data during this study for future analysis would have been likely to be skewed by significant fasting effects if no breakfast had been given. In this context, a variety of ATD-using studies also administer low-protein meals during the depletion procedure (<xref rid="CIT0053" ref-type="bibr">53</xref>&#x02013;<xref rid="CIT0056" ref-type="bibr">56</xref>). In the present sample, we attribute the occurrence of increasing tiredness during the study day to external circumstances, such as the study environment and the long testing period, as opposed to a side effect of the protocol. The missing group effect can be seen as somewhat indicative for this phenomenon. Moreover, breakfast intake could also have impacted side effect ratings as assessed within the present study.</p><p>As stated above, we found an effect of group and time for the somatic complaints score. In the separated item analyses, nausea is the only side effect showing a main effect of time and displays an equal development. Although few ATD studies focused on the examination of side effects, nausea appears to be a frequent problem in these particular studies (<xref rid="CIT0031" ref-type="bibr">31</xref>, <xref rid="CIT0048" ref-type="bibr">48</xref>). It is very likely that the ingestion of a substantial amount of crystalline AAs (Moja-De: 6.5 g/10 kg body weight, ATD<sub>PHE/LEU</sub> 6.2 g/10 kg body weight) that remain in the stomach until dissolution in the acidic environment contributed to the reports of nausea (<xref rid="CIT0057" ref-type="bibr">57</xref>). The missing group effect in somatic complaint investigations partially supports this assumption because all groups were equally affected. Moreover, <italic>post hoc</italic> analyses of the somatic complaints scores revealed a significant difference between BAL and BAL<sub>PHE/LEU</sub> administration as a group effect with an average somatic complaints score four times greater after BAL<sub>PHE/LEU</sub> intake. However, with a maximal somatic complaints score of 24 and a minimal score of 0, the very low mean value observed in this study was not indicative of the intolerability of the new control condition. A modification of the BAL<sub>PHE/LEU</sub> control condition, as mentioned above, might help improve the side effect profile of BAL<sub>PHE/LEU</sub>.</p><p>Presently, there is no ATD-specific validated questionnaire available for somatic complaint or taste assessment. This study provides first questionnaire-based pilot data and certainly requests validation in future ATD studies. In particular, further refinement is needed regarding the gradual and sensible detection of symptom nuances.</p><p>Both positive (PA) and negative (NA) PANAS assessments decreased over the 6-h study duration. In addition to these controversial findings, no group effect was detected, which suggests that the ratings were influenced by the situation during measurements and, perhaps, not a direct consequence of altered brain 5-HT function. This is in agreement with previous findings which suggested that ATD's influence on mood was largely dependent on the susceptibility of the study sample, and this variability led to a lack of clear mood effects in many cases (<xref rid="CIT0058" ref-type="bibr">58</xref>, <xref rid="CIT0059" ref-type="bibr">59</xref>). However, the assessment of mood only served as an ancillary controlling variable in this study, and these results do not significantly impact or question its major findings.</p><p>Although subjects took the amino acid mixtures without any major problems and the new mixture was well tolerated in our study, the uncomfortable palatability seen in all groups certainly requests further modification to ensure trouble-free utilization. Bitterness in general is a problematic issue in all ATD studies as it arises from the specific biochemical structure of polar and hydrophobic groups in some amino acids (<xref rid="CIT0060" ref-type="bibr">60</xref>). The reduction of the overall amount and dose as well as the absence of the worst tasting AAs (i.e. MET, cysteine, and arginine) might have contributed to an easier administration of ATD<sub>PHE/LEU</sub>; however, improvements are still required. For this particular purpose, we suggest to add some of the conventional flavoring supplements, such as vanilla, peppermint, raspberry, and lemonade, with low sugar substitutes to our challenge procedure.</p><p>The between-subjects design is a limitation of this study. Behavioral paradigms conducted as a part of this study (the findings will be the subject of further publications) did not allow for a within-subject repeated measures design due to possible learning effects; a within-subjects design could be used in further investigations.</p><p>Regarding the use of ATD<sub>PHE/LEU</sub> in behavioral studies, the high amount of LEU might present a problem, in particular as LEU is known to alter glutamate formation within the leucine-glutamate cycle (<xref rid="CIT0061" ref-type="bibr">61</xref>, <xref rid="CIT0062" ref-type="bibr">62</xref>). Since LEU might also affect various other parameters, a separate analysis of LEU blood values would be essential to achieve better knowledge of ATD<sub>PHE/LEU</sub>'s metabolic consequences. In this study, we chose the assessment of the BCAAs within a sum parameter for initial investigations as it provides a cost-saving alternative. Moreover, a further aspect that should be considered in future studies would be to add caffeine withdrawal as an additional exclusion criterion since caffeine has been shown to induce alterations in serotonergic neurotransmission (<xref rid="CIT0063" ref-type="bibr">63</xref>, <xref rid="CIT0064" ref-type="bibr">64</xref>).</p><p>The ATD method as a serotonergic challenge tool was criticized by Van Donkelaar et al. in a review article (<xref rid="CIT0065" ref-type="bibr">65</xref>). Specifically, the authors advised caution in interpreting the selective serotonergic effect of ATD-related results, postulating a contribution by various other non-serotonergic mechanisms to diminished 5-HT metabolism (e.g. alterations in cerebrovascular blood flow, stress influence, and metabolic effects). Furthermore, the missing possibility of direct attribution of ATD-induced behavioral alterations to changes in 5-HT neuronal activity was noted. However, many of the suggested mechanisms and the related hypotheses were based on limited data and primarily indirect conclusions. Overall, there is sufficient and convincing evidence that ATD leads to diminished central nervous 5-HT synthesis. In a rodent model, Biskup et al. (<xref rid="CIT0038" ref-type="bibr">38</xref>) demonstrated substantially impaired brain 5-HT synthesis after ATD Moja-De administration. Furthermore, they found a lowered content of 5-HIAA, which is the primary metabolite of 5-HT, and a consequently reduced 5-HT release. As summarized and outlined by Crockett et al. (<xref rid="CIT0066" ref-type="bibr">66</xref>), all of the alternative mechanisms suggested in the aforementioned review would lead to broad attentional and executive impairments that have not been found in any ATD study involving humans. In general, we support the need for further research to gain a solidly grounded understanding of the underlying mechanisms of ATD because the extent of contributions of additional mechanisms cannot be reliably estimated.</p><p>In conclusion, the greater decline in TRP influx rates across the BBB in healthy adults after the dietary administration of the newly developed simplified ATD protocol, ATD<sub>PHE/LEU</sub>, relative to the established ATD Moja-De mixture, was the major finding of this study. The altered composition of ATD<sub>PHE/LEU</sub>, composed of only two LNAAs (PHE and LEU), enabled the reduction in the overall AA amount, had acceptable tolerance, and ensured simplified blood value monitoring due to the reduced components. Nevertheless, this work only represents a first pilot study. Future research is warranted not only to replicate the present findings (optimally a within-subject repeated measures design) but also to improve beverage palatability, its specificity for central nervous 5-HT depletion, and to develop a more suitable balanced control condition (BAL<sub>PHE/LEU</sub>) without significant TRP-related depletion effects. The direct proof of reduced brain 5-HT synthesis in a rodent model (i.e. 5-HT concentrations in brain tissue) would be beneficial, as well as investigations of 5-HIAA levels in human cerebrospinal fluid in order to further validate the newly developed ATD<sub>PHE/LEU</sub> mixture. Moreover, as an additional step, ATD<sub>PHE/LEU</sub> requires further study before administering this mixture to children and adolescents can be considered. If the remaining questions with regard to changes in plasma TRP levels, aspects of specificity, and the respective control condition are clarified, the simplified composition of ATD<sub>PHE/LEU</sub> might have the potential to become an advantageous alternative to the currently available ATD Moja-De protocol for the investigation of the physiological and behavioral effects of reduced central nervous 5-HT synthesis in translational research. However, at this stage, the newly developed ATD<sub>PHE-LEU</sub> mixture needs further validation and is currently not suitable to specifically study central nervous 5-HT function in humans, and at this point in time it cannot replace the ATD Moja-De ATD protocol.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="S1"><caption><title>Dietary tryptophan depletion in humans using a simplified two amino acid formula &#x02013; a pilot study</title></caption><media xlink:href="FNR-60-29272-s001.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><title>Acknowledgements</title><p>This study was funded by the German Federal Ministry of Economics and Technology (Bundesministerium f&#x000fc;r Wirtschaft und Technologie, BMWi) with a grant to the senior author of this article (FDZ). The lead author (ML) was supported by the German Research Council (Deutsche Forschungsgemeinschaft DFG, IRTG 1328).</p></ack><sec sec-type="COI-statement"><title>Conflict of interest and funding</title><p>FDZ was the recipient of an unrestricted award donated by the American Psychiatric Association (APA), the American Psychiatric Institute for Research and Education (APIRE), and AstraZeneca (Young Minds in Psychiatry Award). He has also received research support from the German Federal Ministry for Economics and Technology, the European Union (EU), the German Society for Social Pediatrics and Adolescent Medicine, the Paul and Ursula Klein Foundation, the Dr. August Scheidel Foundation, the IZKF fund of the University Hospital of RWTH Aachen University, the Telethon Perth Childrens&#x02019; Hospital Research Fund (TPCHRF), the Princess Margaret Hospital Foundation, the Telethon Kids Institute, and a travel stipend donated by the GlaxoSmithKline Foundation. He is the recipient of an unrestricted educational grant, travel support, and speaker honoraria by Shire Pharmaceuticals, Germany. In addition, he has received support from the Raine Foundation for Medical Research (Raine Visiting Professorship) and editorial fees from Co-Action Publishing (Sweden). All authors report no conflicts of interest.</p></sec><ref-list><title>References</title><ref id="CIT0001"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zepf</surname><given-names>FD</given-names></name><name><surname>Hood</surname><given-names>S</given-names></name><name><surname>Guillemin</surname><given-names>GJ</given-names></name></person-group><article-title>Food and your mood: nutritional psychiatry</article-title><source>Lancet Psychiatry</source><year>2015</year><volume>2</volume><issue>7</issue><fpage>e19</fpage><pub-id pub-id-type="pmid">26303564</pub-id></element-citation></ref><ref id="CIT0002"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delgado</surname><given-names>PL</given-names></name><name><surname>Charney</surname><given-names>DS</given-names></name><name><surname>Price</surname><given-names>LH</given-names></name><name><surname>Aghajanian</surname><given-names>GK</given-names></name><name><surname>Landis</surname><given-names>H</given-names></name><name><surname>Heninger</surname><given-names>GR</given-names></name></person-group><article-title>Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan</article-title><source>Arch Gen Psychiatr</source><year>1990</year><volume>47</volume><issue>5</issue><fpage>411</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">2184795</pub-id></element-citation></ref><ref id="CIT0003"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kishi</surname><given-names>T</given-names></name><name><surname>Yoshimura</surname><given-names>R</given-names></name><name><surname>Fukuo</surname><given-names>Y</given-names></name><name><surname>Okochi</surname><given-names>T</given-names></name><name><surname>Matsunaga</surname><given-names>S</given-names></name><name><surname>Umene-Nakano</surname><given-names>W</given-names></name><etal/></person-group><article-title>The serotonin 1A receptor gene confer susceptibility to mood disorders: results from an extended meta-analysis of patients with major depression and bipolar disorder</article-title><source>Eur Arch Psychiatr Clin Neurosci</source><year>2013</year><volume>263</volume><issue>2</issue><fpage>105</fpage><lpage>18</lpage></element-citation></ref><ref id="CIT0004"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kotting</surname><given-names>WF</given-names></name><name><surname>Bubenzer</surname><given-names>S</given-names></name><name><surname>Helmbold</surname><given-names>K</given-names></name><name><surname>Eisert</surname><given-names>A</given-names></name><name><surname>Gaber</surname><given-names>TJ</given-names></name><name><surname>Zepf</surname><given-names>FD</given-names></name></person-group><article-title>Effects of tryptophan depletion on reactive aggression and aggressive decision-making in young people with ADHD</article-title><source>Acta Psychiatr Scand</source><year>2013</year><volume>128</volume><issue>2</issue><fpage>114</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">22913430</pub-id></element-citation></ref><ref id="CIT0005"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mette</surname><given-names>C</given-names></name><name><surname>Zimmermann</surname><given-names>M</given-names></name><name><surname>Grabemann</surname><given-names>M</given-names></name><name><surname>Abdel-Hamid</surname><given-names>M</given-names></name><name><surname>Uekermann</surname><given-names>J</given-names></name><name><surname>Biskup</surname><given-names>CS</given-names></name><etal/></person-group><article-title>The impact of acute tryptophan depletion on attentional performance in adult patients with ADHD</article-title><source>Acta Psychiatr Scand</source><year>2013</year><volume>128</volume><issue>2</issue><fpage>124</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">23419004</pub-id></element-citation></ref><ref id="CIT0006"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>KA</given-names></name><name><surname>Fairburn</surname><given-names>CG</given-names></name><name><surname>Cowen</surname><given-names>PJ</given-names></name></person-group><article-title>Symptomatic relapse in bulimia nervosa following acute tryptophan depletion</article-title><source>Arch Gen Psychiatr</source><year>1999</year><volume>56</volume><issue>2</issue><fpage>171</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">10025442</pub-id></element-citation></ref><ref id="CIT0007"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zimmermann</surname><given-names>M</given-names></name><name><surname>Grabemann</surname><given-names>M</given-names></name><name><surname>Mette</surname><given-names>C</given-names></name><name><surname>Abdel-Hamid</surname><given-names>M</given-names></name><name><surname>Uekermann</surname><given-names>J</given-names></name><name><surname>Kraemer</surname><given-names>M</given-names></name><etal/></person-group><article-title>The effects of acute tryptophan depletion on reactive aggression in adults with attention-deficit/hyperactivity disorder (ADHD) and healthy controls</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><issue>3</issue><fpage>e32023</fpage><pub-id pub-id-type="pmid">22431971</pub-id></element-citation></ref><ref id="CIT0008"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biskup</surname><given-names>CS</given-names></name><name><surname>Gaber</surname><given-names>T</given-names></name><name><surname>Helmbold</surname><given-names>K</given-names></name><name><surname>Bubenzer-Busch</surname><given-names>S</given-names></name><name><surname>Zepf</surname><given-names>FD</given-names></name></person-group><article-title>Amino acid challenge and depletion techniques in human functional neuroimaging studies: an overview</article-title><source>Amino Acids</source><year>2015</year><volume>47</volume><issue>4</issue><fpage>651</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">25772814</pub-id></element-citation></ref><ref id="CIT0009"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Helmbold</surname><given-names>K</given-names></name><name><surname>Zvyagintsev</surname><given-names>M</given-names></name><name><surname>Dahmen</surname><given-names>B</given-names></name><name><surname>Bubenzer-Busch</surname><given-names>S</given-names></name><name><surname>Gaber</surname><given-names>TJ</given-names></name><name><surname>Crockett</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Effects of serotonin depletion on punishment processing in the orbitofrontal and anterior cingulate cortices of healthy women</article-title><source>Eur Neuropsychopharmacol</source><year>2015</year><volume>25</volume><issue>6</issue><fpage>846</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">25869157</pub-id></element-citation></ref><ref id="CIT0010"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hildebrand</surname><given-names>P</given-names></name><name><surname>K&#x000f6;nigschulte</surname><given-names>W</given-names></name><name><surname>Gaber</surname><given-names>TJ</given-names></name><name><surname>Bubenzer-Busch</surname><given-names>S</given-names></name><name><surname>Helmbold</surname><given-names>K</given-names></name><name><surname>Biskup</surname><given-names>CS</given-names></name><etal/></person-group><article-title>Effects of dietary tryptophan and phenylalanine&#x02013;tyrosine depletion on phasic alertness in healthy adults&#x02013;a pilot study</article-title><source>Food Nutr Res</source><year>2015</year><volume>59</volume><fpage>26407</fpage><pub-id pub-id-type="pmid">25933613</pub-id></element-citation></ref><ref id="CIT0011"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanchez</surname><given-names>CL</given-names></name><name><surname>Biskup</surname><given-names>CS</given-names></name><name><surname>Herpertz</surname><given-names>S</given-names></name><name><surname>Gaber</surname><given-names>TJ</given-names></name><name><surname>Kuhn</surname><given-names>CM</given-names></name><name><surname>Hood</surname><given-names>SH</given-names></name><etal/></person-group><article-title>The role of serotonin (5-HT) in behavioral control: findings from animal research and clinical implications</article-title><source>Int J Neuropsychopharmacol</source><year>2015</year><volume>18</volume><issue>10</issue><fpage>pyv050</fpage><pub-id pub-id-type="pmid">25991656</pub-id></element-citation></ref><ref id="CIT0012"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>S&#x000e1;nchez</surname><given-names>CL</given-names></name><name><surname>Van Swearingen</surname><given-names>AE</given-names></name><name><surname>Arrant</surname><given-names>AE</given-names></name><name><surname>Biskup</surname><given-names>CS</given-names></name><name><surname>Kuhn</surname><given-names>CM</given-names></name><name><surname>Zepf</surname><given-names>FD</given-names></name></person-group><article-title>Simplified dietary acute tryptophan depletion: effects of a novel amino acid mixture on the neurochemistry of C57BL/6J mice</article-title><source>Food Nutr Res</source><year>2015</year><volume>59</volume><fpage>27424</fpage><pub-id pub-id-type="pmid">26278978</pub-id></element-citation></ref><ref id="CIT0013"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaber</surname><given-names>TJ</given-names></name><name><surname>Dingerkus</surname><given-names>VL</given-names></name><name><surname>Crockett</surname><given-names>MJ</given-names></name><name><surname>Bubenzer-Busch</surname><given-names>S</given-names></name><name><surname>Helmbold</surname><given-names>K</given-names></name><name><surname>S&#x000e1;nchez</surname><given-names>CL</given-names></name><etal/></person-group><article-title>Studying the effects of dietary body weight adjusted acute tryptophan depletion on punishment-related behavioral inhibition</article-title><source>Food Nutr Res</source><year>2015</year><volume>59</volume><fpage>28443</fpage><pub-id pub-id-type="pmid">26268708</pub-id></element-citation></ref><ref id="CIT0014"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pardridge</surname><given-names>WM</given-names></name><name><surname>Oldendorf</surname><given-names>WH</given-names></name></person-group><article-title>Kinetic analysis of blood-brain barrier transport of amino acids</article-title><source>Biochim Biophys Acta</source><year>1975</year><volume>401</volume><issue>1</issue><fpage>128</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">1148286</pub-id></element-citation></ref><ref id="CIT0015"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oldendorf</surname><given-names>WH</given-names></name><name><surname>Szabo</surname><given-names>J</given-names></name></person-group><article-title>Amino acid assignment to one of three blood-brain barrier amino acid carriers</article-title><source>Am J Physiol</source><year>1976</year><volume>230</volume><issue>1</issue><fpage>94</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">1251917</pub-id></element-citation></ref><ref id="CIT0016"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>QR</given-names></name><name><surname>Momma</surname><given-names>S</given-names></name><name><surname>Aoyagi</surname><given-names>M</given-names></name><name><surname>Rapoport</surname><given-names>SI</given-names></name></person-group><article-title>Kinetics of neutral amino acid transport across the blood-brain barrier</article-title><source>J Neurochem</source><year>1987</year><volume>49</volume><issue>5</issue><fpage>1651</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">3668544</pub-id></element-citation></ref><ref id="CIT0017"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>QR</given-names></name><name><surname>Takasato</surname><given-names>Y</given-names></name></person-group><article-title>Kinetics of amino acid transport at the blood-brain barrier studied using an in situ brain perfusion technique</article-title><source>Ann N Y Acad Sci</source><year>1986</year><volume>481</volume><fpage>186</fpage><lpage>201</lpage><pub-id pub-id-type="pmid">3468857</pub-id></element-citation></ref><ref id="CIT0018"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moja</surname><given-names>EA</given-names></name><name><surname>Restani</surname><given-names>P</given-names></name><name><surname>Corsini</surname><given-names>E</given-names></name><name><surname>Stacchezzini</surname><given-names>MC</given-names></name><name><surname>Assereto</surname><given-names>R</given-names></name><name><surname>Galli</surname><given-names>CL</given-names></name></person-group><article-title>Cycloheximide blocks the fall of plasma and tissue tryptophan levels after tryptophan-free amino acid mixtures</article-title><source>Life Sci</source><year>1991</year><volume>49</volume><issue>15</issue><fpage>1121</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">1895873</pub-id></element-citation></ref><ref id="CIT0019"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wurtman</surname><given-names>RJ</given-names></name><name><surname>Hefti</surname><given-names>F</given-names></name><name><surname>Melamed</surname><given-names>E</given-names></name></person-group><article-title>Precursor control of neurotransmitter synthesis</article-title><source>Pharmacol Rev</source><year>1980</year><volume>32</volume><issue>4</issue><fpage>315</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">6115400</pub-id></element-citation></ref><ref id="CIT0020"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marsh</surname><given-names>DM</given-names></name><name><surname>Dougherty</surname><given-names>DM</given-names></name><name><surname>Moeller</surname><given-names>FG</given-names></name><name><surname>Swann</surname><given-names>AC</given-names></name><name><surname>Spiga</surname><given-names>R</given-names></name></person-group><article-title>Laboratory-measured aggressive behavior of women: acute tryptophan depletion and augmentation</article-title><source>Neuropsychopharmacology</source><year>2002</year><volume>26</volume><issue>5</issue><fpage>660</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">11927191</pub-id></element-citation></ref><ref id="CIT0021"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dougherty</surname><given-names>DM</given-names></name><name><surname>Marsh-Richard</surname><given-names>DM</given-names></name><name><surname>Mathias</surname><given-names>CW</given-names></name><name><surname>Hood</surname><given-names>AJ</given-names></name><name><surname>Addicott</surname><given-names>MA</given-names></name><name><surname>Moeller</surname><given-names>FG</given-names></name><etal/></person-group><article-title>Comparison of 50- and 100-g L-tryptophan depletion and loading formulations for altering 5-HT synthesis: pharmacokinetics, side effects, and mood states</article-title><source>Psychopharmacology (Berl)</source><year>2008</year><volume>198</volume><issue>3</issue><fpage>431</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">18452034</pub-id></element-citation></ref><ref id="CIT0022"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernstrom</surname><given-names>JD</given-names></name></person-group><article-title>Role of precursor availability in control of monoamine biosynthesis in brain</article-title><source>Physiol Rev</source><year>1983</year><volume>63</volume><issue>2</issue><fpage>484</fpage><lpage>546</lpage><pub-id pub-id-type="pmid">6132421</pub-id></element-citation></ref><ref id="CIT0023"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chanut</surname><given-names>E</given-names></name><name><surname>Zini</surname><given-names>R</given-names></name><name><surname>Trouvin</surname><given-names>JH</given-names></name><name><surname>Riant</surname><given-names>P</given-names></name><name><surname>Tillement</surname><given-names>JP</given-names></name><name><surname>Jacquot</surname><given-names>C</given-names></name></person-group><article-title>Albumin binding and brain uptake of 6-fluoro-DL-tryptophan: competition with L-tryptophan</article-title><source>Biochem Pharmacol</source><year>1992</year><volume>44</volume><issue>10</issue><fpage>2082</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">1449526</pub-id></element-citation></ref><ref id="CIT0024"><label>24</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Frazer</surname><given-names>A</given-names></name><name><surname>Hensler</surname><given-names>JG</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Siegel</surname><given-names>GJ</given-names></name><name><surname>Agranoff</surname><given-names>BW</given-names></name><name><surname>Albers</surname><given-names>RW</given-names></name><name><surname>Molinoff</surname><given-names>PB</given-names></name></person-group><article-title>Serotonin</article-title><source>Basic neurochemistry: molecular, cellular and medical aspects</source><year>1994</year><publisher-loc>New York</publisher-loc><publisher-name>Raven Press</publisher-name><fpage>283</fpage><lpage>308</lpage></element-citation></ref><ref id="CIT0025"><label>25</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Marsden</surname><given-names>CA</given-names></name></person-group><person-group person-group-type="author"><name><surname>Feighner</surname><given-names>JP</given-names></name><name><surname>Boyer</surname><given-names>WF</given-names></name></person-group><article-title>The neuropharmacology of serotonin in the central nervous system</article-title><source>Selective serotonin re-uptake inhibitors</source><year>1996</year><publisher-loc>Chichester</publisher-loc><publisher-name>Wiley</publisher-name><fpage>1</fpage><lpage>34</lpage></element-citation></ref><ref id="CIT0026"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dingerkus</surname><given-names>VL</given-names></name><name><surname>Gaber</surname><given-names>TJ</given-names></name><name><surname>Helmbold</surname><given-names>K</given-names></name><name><surname>Bubenzer</surname><given-names>S</given-names></name><name><surname>Eisert</surname><given-names>A</given-names></name><name><surname>Sanchez</surname><given-names>CL</given-names></name><etal/></person-group><article-title>Acute tryptophan depletion in accordance with body weight: influx of amino acids across the blood-brain barrier</article-title><source>J Neural Transm (Vienna)</source><year>2012</year><volume>119</volume><issue>9</issue><fpage>1037</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">22622364</pub-id></element-citation></ref><ref id="CIT0027"><label>27</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Zepf</surname><given-names>F</given-names></name></person-group><person-group person-group-type="editor"><name><surname>D&#x02019;Mello</surname><given-names>J</given-names></name></person-group><article-title>Principles of rapid tryptophan depletion and its use in research on neuropsychiatric disorders</article-title><source>Amino acids in human nutrition and health</source><year>2012</year><publisher-loc>Oxfordshire</publisher-loc><publisher-name>Cabi</publisher-name><fpage>418</fpage><lpage>26</lpage></element-citation></ref><ref id="CIT0028"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Concu</surname><given-names>A</given-names></name><name><surname>Fadda</surname><given-names>F</given-names></name><name><surname>Blanco</surname><given-names>S</given-names></name><name><surname>Congia</surname><given-names>S</given-names></name><name><surname>Lostia</surname><given-names>M</given-names></name></person-group><article-title>Mental changes induced by the oral administration of tryptophan-free amino acid mixtures in man</article-title><source>IRCS Med Sci</source><year>1977</year><volume>5</volume><fpage>520</fpage></element-citation></ref><ref id="CIT0029"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fadda</surname><given-names>F</given-names></name></person-group><article-title>Tryptophan-free diets: a physiological tool to study brain serotonin function</article-title><source>News Physiol Sci</source><year>2000</year><volume>15</volume><fpage>260</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">11390922</pub-id></element-citation></ref><ref id="CIT0030"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moja</surname><given-names>EA</given-names></name><name><surname>Stoff</surname><given-names>DM</given-names></name><name><surname>Gessa</surname><given-names>GL</given-names></name><name><surname>Castoldi</surname><given-names>D</given-names></name><name><surname>Assereto</surname><given-names>R</given-names></name><name><surname>Tofanetti</surname><given-names>O</given-names></name></person-group><article-title>Decrease in plasma tryptophan after tryptophan-free amino acid mixtures in man</article-title><source>Life Sci</source><year>1988</year><volume>42</volume><issue>16</issue><fpage>1551</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">3352467</pub-id></element-citation></ref><ref id="CIT0031"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>SN</given-names></name><name><surname>Smith</surname><given-names>SE</given-names></name><name><surname>Pihl</surname><given-names>RO</given-names></name><name><surname>Ervin</surname><given-names>FR</given-names></name></person-group><article-title>Tryptophan depletion causes a rapid lowering of mood in normal males</article-title><source>Psychopharmacology</source><year>1985</year><volume>87</volume><issue>2</issue><fpage>173</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">3931142</pub-id></element-citation></ref><ref id="CIT0032"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Booij</surname><given-names>L</given-names></name><name><surname>Van der Does</surname><given-names>AJ</given-names></name><name><surname>Haffmans</surname><given-names>PM</given-names></name><name><surname>Spinhoven</surname><given-names>P</given-names></name><name><surname>McNally</surname><given-names>RJ</given-names></name></person-group><article-title>Acute tryptophan depletion as a model of depressive relapse: behavioural specificity and ethical considerations</article-title><source>Br J Psychiatr</source><year>2005</year><volume>187</volume><fpage>148</fpage><lpage>54</lpage></element-citation></ref><ref id="CIT0033"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>PP</given-names></name><name><surname>Cleare</surname><given-names>AJ</given-names></name><name><surname>Lee</surname><given-names>F</given-names></name><name><surname>Fusar-Poli</surname><given-names>P</given-names></name><name><surname>Tunstall</surname><given-names>N</given-names></name><name><surname>Fu</surname><given-names>CH</given-names></name><etal/></person-group><article-title>Effect of acute tryptophan depletion on pre-frontal engagement</article-title><source>Psychopharmacology</source><year>2006</year><volume>187</volume><issue>4</issue><fpage>486</fpage><lpage>97</lpage><pub-id pub-id-type="pmid">16823591</pub-id></element-citation></ref><ref id="CIT0034"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klaassen</surname><given-names>T</given-names></name><name><surname>Riedel</surname><given-names>WJ</given-names></name><name><surname>Deutz</surname><given-names>NE</given-names></name><name><surname>Van Someren</surname><given-names>A</given-names></name><name><surname>Van Praag</surname><given-names>HM</given-names></name></person-group><article-title>Specificity of the tryptophan depletion method</article-title><source>Psychopharmacology</source><year>1999</year><volume>141</volume><issue>3</issue><fpage>279</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">10027509</pub-id></element-citation></ref><ref id="CIT0035"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moeller</surname><given-names>FG</given-names></name><name><surname>Dougherty</surname><given-names>DM</given-names></name><name><surname>Swann</surname><given-names>AC</given-names></name><name><surname>Collins</surname><given-names>D</given-names></name><name><surname>Davis</surname><given-names>CM</given-names></name><name><surname>Cherek</surname><given-names>DR</given-names></name></person-group><article-title>Tryptophan depletion and aggressive responding in healthy males</article-title><source>Psychopharmacology</source><year>1996</year><volume>126</volume><issue>2</issue><fpage>97</fpage><lpage>103</lpage><pub-id pub-id-type="pmid">8856827</pub-id></element-citation></ref><ref id="CIT0036"><label>36</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Kewitz</surname><given-names>A</given-names></name></person-group><source>Biochemische Untersuchungen zur Optimierung des &#x02018;Rapid Tryptophan Depletion-Test&#x02019; (RTD): Eine physiologische Methode zur akuten Verminderung der zentrainerv&#x000f6;sen Serotonin-Synthese in der psychobiologischen Forschung</source><year>2002</year><publisher-name>Johann Wolfgang Goethe-Universit&#x000e4;t zu Frankfurt am Main</publisher-name></element-citation></ref><ref id="CIT0037"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Demisch</surname><given-names>L</given-names></name><name><surname>Kewitz</surname><given-names>A</given-names></name><name><surname>Schmeck</surname><given-names>K</given-names></name><name><surname>Sadigorsky</surname><given-names>S</given-names></name><name><surname>Barta</surname><given-names>S</given-names></name><name><surname>Dierks</surname><given-names>T</given-names></name><etal/></person-group><article-title>Methodology of rapid tryptophan depletion (RTD): impact of gender and body weight</article-title><source>Eur Arch Psychiatry Clin Neurosci</source><year>2002</year><volume>252</volume><issue>2</issue><fpage>1</fpage><pub-id pub-id-type="pmid">12056575</pub-id></element-citation></ref><ref id="CIT0038"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biskup</surname><given-names>CS</given-names></name><name><surname>Sanchez</surname><given-names>CL</given-names></name><name><surname>Arrant</surname><given-names>A</given-names></name><name><surname>Van Swearingen</surname><given-names>AE</given-names></name><name><surname>Kuhn</surname><given-names>C</given-names></name><name><surname>Zepf</surname><given-names>FD</given-names></name></person-group><article-title>Effects of acute tryptophan depletion on brain serotonin function and concentrations of dopamine and norepinephrine in C57BL/6J and BALB/cJ mice</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><issue>5</issue><fpage>e35916</fpage><pub-id pub-id-type="pmid">22629305</pub-id></element-citation></ref><ref id="CIT0039"><label>39</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Demal</surname><given-names>U</given-names></name></person-group><source>SKIDPIT-light Screeningbogen</source><year>1999</year><publisher-name>Universit&#x000e4;t Wien</publisher-name></element-citation></ref><ref id="CIT0040"><label>40</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Wei&#x000df;</surname><given-names>R</given-names></name></person-group><source>Grundintelligenztest skala 2 &#x02013; revision CFT 20-R [Culture fair intelligence test scale 2 &#x02013; revision]</source><year>2006</year><publisher-loc>G&#x000f6;ttingen</publisher-loc><publisher-name>Hogrefe</publisher-name></element-citation></ref><ref id="CIT0041"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zepf</surname><given-names>FD</given-names></name><name><surname>Poustka</surname><given-names>F</given-names></name></person-group><article-title>5-HT functioning and aggression in children with ADHD and disruptive behaviour disorders</article-title><source>Hum Psychopharmacol</source><year>2008</year><volume>23</volume><issue>5</issue><fpage>438</fpage></element-citation></ref><ref id="CIT0042"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zepf</surname><given-names>FD</given-names></name><name><surname>Wockel</surname><given-names>L</given-names></name><name><surname>Poustka</surname><given-names>F</given-names></name><name><surname>Holtmann</surname><given-names>M</given-names></name></person-group><article-title>Dietary tryptophan depletion according to body weight &#x02013; a new treatment option in acute mania?</article-title><source>Med Hypotheses</source><year>2009</year><volume>72</volume><issue>1</issue><fpage>47</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">18849122</pub-id></element-citation></ref><ref id="CIT0043"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zepf</surname><given-names>FD</given-names></name><name><surname>Stadler</surname><given-names>C</given-names></name><name><surname>Demisch</surname><given-names>L</given-names></name><name><surname>Schmitt</surname><given-names>M</given-names></name><name><surname>Landgraf</surname><given-names>M</given-names></name><name><surname>Poustka</surname><given-names>F</given-names></name></person-group><article-title>Serotonergic functioning and trait-impulsivity in attention-deficit/hyperactivity-disordered boys (ADHD): influence of rapid tryptophan depletion</article-title><source>Hum Psychopharmacol</source><year>2008</year><volume>23</volume><issue>1</issue><fpage>43</fpage><lpage>51</lpage></element-citation></ref><ref id="CIT0044"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zepf</surname><given-names>F</given-names></name><name><surname>Holtmann</surname><given-names>M</given-names></name><name><surname>Stadler</surname><given-names>C</given-names></name><name><surname>Demisch</surname><given-names>L</given-names></name><name><surname>Schmitt</surname><given-names>M</given-names></name><name><surname>W&#x000f6;ckel</surname><given-names>L</given-names></name><etal/></person-group><article-title>Diminished serotonergic functioning in hostile children with ADHD: tryptophan depletion increases behavioural inhibition</article-title><source>Pharmacopsychiatry</source><year>2008</year><volume>41</volume><issue>2</issue><fpage>60</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">18311686</pub-id></element-citation></ref><ref id="CIT0045"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pardridge</surname><given-names>WM</given-names></name></person-group><article-title>Brain metabolism: a perspective from the blood-brain barrier</article-title><source>Physiol Rev</source><year>1983</year><volume>63</volume><issue>4</issue><fpage>1481</fpage><lpage>535</lpage><pub-id pub-id-type="pmid">6361813</pub-id></element-citation></ref><ref id="CIT0046"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Helmbold</surname><given-names>K</given-names></name><name><surname>Bubenzer</surname><given-names>S</given-names></name><name><surname>Dahmen</surname><given-names>B</given-names></name><name><surname>Eisert</surname><given-names>A</given-names></name><name><surname>Gaber</surname><given-names>TJ</given-names></name><name><surname>Habel</surname><given-names>U</given-names></name><etal/></person-group><article-title>Influence of acute tryptophan depletion on verbal declarative episodic memory in young adult females</article-title><source>Amino Acids</source><year>2013</year><volume>45</volume><issue>5</issue><fpage>1207</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">24072504</pub-id></element-citation></ref><ref id="CIT0047"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watson</surname><given-names>D</given-names></name><name><surname>Clark</surname><given-names>LA</given-names></name><name><surname>Tellegen</surname><given-names>A</given-names></name></person-group><article-title>Development and validation of brief measures of positive and negative affect: the PANAS scales</article-title><source>J Pers Soc Psychol</source><year>1988</year><volume>54</volume><issue>6</issue><fpage>1063</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">3397865</pub-id></element-citation></ref><ref id="CIT0048"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>aan het Rot</surname><given-names>M</given-names></name><name><surname>Benkelfat</surname><given-names>C</given-names></name><name><surname>Boivin</surname><given-names>DB</given-names></name><name><surname>Young</surname><given-names>SN</given-names></name></person-group><article-title>Bright light exposure during acute tryptophan depletion prevents a lowering of mood in mildly seasonal women</article-title><source>Eur Neuropsychopharmacol</source><year>2008</year><volume>18</volume><issue>1</issue><fpage>14</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">17582745</pub-id></element-citation></ref><ref id="CIT0049"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stadler</surname><given-names>C</given-names></name><name><surname>Zepf</surname><given-names>FD</given-names></name><name><surname>Demisch</surname><given-names>L</given-names></name><name><surname>Schmitt</surname><given-names>M</given-names></name><name><surname>Landgraf</surname><given-names>M</given-names></name><name><surname>Poustka</surname><given-names>F</given-names></name></person-group><article-title>Influence of rapid tryptophan depletion on laboratory-provoked aggression in children with ADHD</article-title><source>Neuropsychobiology</source><year>2007</year><volume>56</volume><issue>2&#x02013;3</issue><fpage>104</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">18182830</pub-id></element-citation></ref><ref id="CIT0050"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zepf</surname><given-names>FD</given-names></name><name><surname>Wockel</surname><given-names>L</given-names></name><name><surname>Poustka</surname><given-names>F</given-names></name><name><surname>Holtmann</surname><given-names>M</given-names></name></person-group><article-title>Diminished 5-HT functioning in CBCL pediatric bipolar disorder-profiled ADHD patients versus normal ADHD: susceptibility to rapid tryptophan depletion influences reaction time performance</article-title><source>Hum Psychopharmacol</source><year>2008</year><volume>23</volume><issue>4</issue><fpage>291</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">18421802</pub-id></element-citation></ref><ref id="CIT0051"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishizawa</surname><given-names>S</given-names></name><name><surname>Benkelfat</surname><given-names>C</given-names></name><name><surname>Young</surname><given-names>SN</given-names></name><name><surname>Leyton</surname><given-names>M</given-names></name><name><surname>Mzengeza</surname><given-names>S</given-names></name><name><surname>de Montigny</surname><given-names>C</given-names></name><etal/></person-group><article-title>Differences between males and females in rates of serotonin synthesis in human brain</article-title><source>Proc Natl Acad Sci USA</source><year>1997</year><volume>94</volume><issue>10</issue><fpage>5308</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">9144233</pub-id></element-citation></ref><ref id="CIT0052"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Badawy</surname><given-names>AA</given-names></name><name><surname>Dougherty</surname><given-names>DM</given-names></name><name><surname>Richard</surname><given-names>DM</given-names></name></person-group><article-title>Specificity of the acute tryptophan and tyrosine plus phenylalanine depletion and loading tests part II: normalisation of the tryptophan and the tyrosine plus phenylalanine to competing amino acid ratios in a new control formulation</article-title><source>Int J Tryptophan Res</source><year>2010</year><volume>3</volume><fpage>35</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">20725610</pub-id></element-citation></ref><ref id="CIT0053"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riedel</surname><given-names>WJ</given-names></name><name><surname>Klaassen</surname><given-names>T</given-names></name><name><surname>Deutz</surname><given-names>NE</given-names></name><name><surname>Van Someren</surname><given-names>A</given-names></name><name><surname>Van Praag</surname><given-names>HM</given-names></name></person-group><article-title>Tryptophan depletion in normal volunteers produces selective impairment in memory consolidation</article-title><source>Psychopharmacology</source><year>1999</year><volume>141</volume><issue>4</issue><fpage>362</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">10090643</pub-id></element-citation></ref><ref id="CIT0054"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmitt</surname><given-names>JA</given-names></name><name><surname>Jorissen</surname><given-names>BL</given-names></name><name><surname>Sobczak</surname><given-names>S</given-names></name><name><surname>Van Boxtel</surname><given-names>MP</given-names></name><name><surname>Hogervorst</surname><given-names>E</given-names></name><name><surname>Deutz</surname><given-names>NE</given-names></name><etal/></person-group><article-title>Tryptophan depletion impairs memory consolidation but improves focussed attention in healthy young volunteers</article-title><source>J Psychopharmacol</source><year>2000</year><volume>14</volume><issue>1</issue><fpage>21</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">10757249</pub-id></element-citation></ref><ref id="CIT0055"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sobczak</surname><given-names>S</given-names></name><name><surname>Riedel</surname><given-names>WJ</given-names></name><name><surname>Booij</surname><given-names>I</given-names></name><name><surname>Aan Het Rot</surname><given-names>M</given-names></name><name><surname>Deutz</surname><given-names>NE</given-names></name><name><surname>Honig</surname><given-names>A</given-names></name></person-group><article-title>Cognition following acute tryptophan depletion: difference between first-degree relatives of bipolar disorder patients and matched healthy control volunteers</article-title><source>Psychol Med</source><year>2002</year><volume>32</volume><issue>3</issue><fpage>503</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">11989995</pub-id></element-citation></ref><ref id="CIT0056"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evers</surname><given-names>EA</given-names></name><name><surname>Sambeth</surname><given-names>A</given-names></name><name><surname>Ramaekers</surname><given-names>JG</given-names></name><name><surname>Riedel</surname><given-names>WJ</given-names></name><name><surname>Van der Veen</surname><given-names>FM</given-names></name></person-group><article-title>The effects of acute tryptophan depletion on brain activation during cognition and emotional processing in healthy volunteers</article-title><source>Curr Pharm Des</source><year>2010</year><volume>16</volume><issue>18</issue><fpage>1998</fpage><lpage>2011</lpage><pub-id pub-id-type="pmid">20370668</pub-id></element-citation></ref><ref id="CIT0057"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>SN</given-names></name></person-group><article-title>Acute tryptophan depletion in humans: a review of theoretical, practical and ethical aspects</article-title><source>J Psychiatry Neurosci</source><year>2013</year><volume>38</volume><issue>5</issue><fpage>294</fpage><lpage>305</lpage><pub-id pub-id-type="pmid">23428157</pub-id></element-citation></ref><ref id="CIT0058"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>SN</given-names></name><name><surname>Leyton</surname><given-names>M</given-names></name></person-group><article-title>The role of serotonin in human mood and social interaction. Insight from altered tryptophan levels</article-title><source>Pharmacol Biochem Behav</source><year>2002</year><volume>71</volume><issue>4</issue><fpage>857</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">11888576</pub-id></element-citation></ref><ref id="CIT0059"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Booij</surname><given-names>L</given-names></name><name><surname>Van der Does</surname><given-names>W</given-names></name><name><surname>Benkelfat</surname><given-names>C</given-names></name><name><surname>Bremner</surname><given-names>JD</given-names></name><name><surname>Cowen</surname><given-names>PJ</given-names></name><name><surname>Fava</surname><given-names>M</given-names></name><etal/></person-group><article-title>Predictors of mood response to acute tryptophan depletion. A reanalysis</article-title><source>Neuropsychopharmacology</source><year>2002</year><volume>27</volume><issue>5</issue><fpage>852</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">12431859</pub-id></element-citation></ref><ref id="CIT0060"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wieser</surname><given-names>H</given-names></name><name><surname>Belitz</surname><given-names>HD</given-names></name></person-group><article-title>Relations between structure and bitter taste of amino acids and peptides. I. Amino acids and related compounds</article-title><source>Z Lebensm Unters Forsch</source><year>1975</year><volume>159</volume><issue>2</issue><fpage>65</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">1229718</pub-id></element-citation></ref><ref id="CIT0061"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yudkoff</surname><given-names>M</given-names></name></person-group><article-title>Brain metabolism of branched-chain amino acids</article-title><source>Glia</source><year>1997</year><volume>21</volume><issue>1</issue><fpage>92</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">9298851</pub-id></element-citation></ref><ref id="CIT0062"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hutson</surname><given-names>SM</given-names></name><name><surname>Lieth</surname><given-names>E</given-names></name><name><surname>LaNoue</surname><given-names>KF</given-names></name></person-group><article-title>Function of leucine in excitatory neurotransmitter metabolism in the central nervous system</article-title><source>J Nutr</source><year>2001</year><volume>131</volume><issue>3</issue><fpage>846s</fpage><lpage>50s</lpage><pub-id pub-id-type="pmid">11238772</pub-id></element-citation></ref><ref id="CIT0063"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khaliq</surname><given-names>S</given-names></name><name><surname>Haider</surname><given-names>S</given-names></name><name><surname>Naqvi</surname><given-names>F</given-names></name><name><surname>Perveen</surname><given-names>T</given-names></name><name><surname>Saleem</surname><given-names>S</given-names></name><name><surname>Haleem</surname><given-names>DJ</given-names></name></person-group><article-title>Altered brain serotonergic neurotransmission following caffeine withdrawal produces behavioral deficits in rats</article-title><source>Pak J Pharm Sci</source><year>2012</year><volume>25</volume><issue>1</issue><fpage>21</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">22186305</pub-id></element-citation></ref><ref id="CIT0064"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haleem</surname><given-names>DJ</given-names></name><name><surname>Yasmeen</surname><given-names>A</given-names></name><name><surname>Haleem</surname><given-names>M</given-names></name><name><surname>Zafar</surname><given-names>A</given-names></name></person-group><article-title>24h withdrawal following repeated administration of caffeine attenuates brain serotonin but not tryptophan in rat brain: implications for caffeine-induced depression</article-title><source>Life Sci</source><year>1995</year><volume>57</volume><issue>19</issue><fpage>PL285</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">7475912</pub-id></element-citation></ref><ref id="CIT0065"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Donkelaar</surname><given-names>EL</given-names></name><name><surname>Blokland</surname><given-names>A</given-names></name><name><surname>Ferrington</surname><given-names>L</given-names></name><name><surname>Kelly</surname><given-names>PA</given-names></name><name><surname>Steinbusch</surname><given-names>HW</given-names></name><name><surname>Prickaerts</surname><given-names>J</given-names></name></person-group><article-title>Mechanism of acute tryptophan depletion: is it only serotonin?</article-title><source>Mol Psychiatry</source><year>2011</year><volume>16</volume><issue>7</issue><fpage>695</fpage><lpage>713</lpage><pub-id pub-id-type="pmid">21339754</pub-id></element-citation></ref><ref id="CIT0066"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crockett</surname><given-names>MJ</given-names></name><name><surname>Clark</surname><given-names>L</given-names></name><name><surname>Roiser</surname><given-names>JP</given-names></name><name><surname>Robinson</surname><given-names>OJ</given-names></name><name><surname>Cools</surname><given-names>R</given-names></name><name><surname>Chase</surname><given-names>HW</given-names></name><etal/></person-group><article-title>Converging evidence for central 5-HT effects in acute tryptophan depletion</article-title><source>Mol Psychiatry</source><year>2012</year><volume>17</volume><issue>2</issue><fpage>121</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">21876544</pub-id></element-citation></ref></ref-list></back></article>